<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD005965" GROUP_ID="INFECTN" ID="793201052414372449" MERGED_FROM="" MODIFIED="2008-08-11 16:33:38 +0200" MODIFIED_BY="Reive Robb" REVIEW_NO="AOMA" REVMAN_SUB_VERSION="5.0.14" REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="3.0">
<COVER_SHEET MODIFIED="2008-08-11 16:33:38 +0200" MODIFIED_BY="Reive Robb">
<TITLE>Artemether-lumefantrine (four-dose regimen) for treating uncomplicated falciparum malaria</TITLE>
<CONTACT MODIFIED="2008-08-11 16:33:38 +0200" MODIFIED_BY="Reive Robb"><PERSON ID="14320" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Aika</FIRST_NAME><MIDDLE_INITIALS>AA</MIDDLE_INITIALS><LAST_NAME>Omari</LAST_NAME><POSITION>Specialist Registrar in Infectious Diseases</POSITION><EMAIL_1>aomari@nhs.net</EMAIL_1><EMAIL_2>aika@omari1677.freeserve.co.uk</EMAIL_2><ADDRESS><ORGANISATION>Alder Hey Children's Hospital</ORGANISATION><ADDRESS_1>Eaton Road</ADDRESS_1><CITY>Liverpool</CITY><ZIP>L12 2AP</ZIP><COUNTRY CODE="GB">UK</COUNTRY></ADDRESS></PERSON></CONTACT>
<CREATORS MODIFIED="2008-08-11 16:33:38 +0200" MODIFIED_BY="Reive Robb"><PERSON ID="14320" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Aika</FIRST_NAME><MIDDLE_INITIALS>AA</MIDDLE_INITIALS><LAST_NAME>Omari</LAST_NAME><POSITION>Specialist Registrar in Infectious Diseases</POSITION><EMAIL_1>aomari@nhs.net</EMAIL_1><EMAIL_2>aika@omari1677.freeserve.co.uk</EMAIL_2><ADDRESS><ORGANISATION>Alder Hey Children's Hospital</ORGANISATION><ADDRESS_1>Eaton Road</ADDRESS_1><CITY>Liverpool</CITY><ZIP>L12 2AP</ZIP><COUNTRY CODE="GB">UK</COUNTRY></ADDRESS></PERSON><PERSON ID="14297" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Carrol</FIRST_NAME><MIDDLE_INITIALS>L</MIDDLE_INITIALS><LAST_NAME>Gamble</LAST_NAME><POSITION>Lecturer in Medical Statistics</POSITION><EMAIL_1>c.gamble@liv.ac.uk</EMAIL_1><ADDRESS><DEPARTMENT>Centre for Medical Statistics and Health Evaluation</DEPARTMENT><ORGANISATION>University of Liverpool</ORGANISATION><ADDRESS_1>Shelley's Cottage</ADDRESS_1><ADDRESS_2>Brownlow Street</ADDRESS_2><CITY>Liverpool</CITY><ZIP>L69 3GS</ZIP><COUNTRY CODE="GB">UK</COUNTRY><PHONE_1>+44 151 794 4059</PHONE_1></ADDRESS></PERSON><PERSON ID="7492" ROLE="AUTHOR"><PREFIX>Prof</PREFIX><FIRST_NAME>Paul</FIRST_NAME><LAST_NAME>Garner</LAST_NAME><EMAIL_1>pgarner@liv.ac.uk</EMAIL_1><ADDRESS><DEPARTMENT>International Health Group</DEPARTMENT><ORGANISATION>Liverpool School of Tropical Medicine</ORGANISATION><ADDRESS_1>Pembroke Place</ADDRESS_1><CITY>Liverpool</CITY><ZIP>L3 5QA</ZIP><REGION>Merseyside</REGION><COUNTRY CODE="GB">UK</COUNTRY><PHONE_1>+44 151 705 3201</PHONE_1><FAX_1>+44 151 705 3364</FAX_1></ADDRESS></PERSON></CREATORS>
<DATES MODIFIED="2008-07-18 12:06:12 +0100" MODIFIED_BY="[Empty name]">
<UP_TO_DATE>
<DATE DAY="20" MONTH="1" YEAR="2006"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="20" MONTH="1" YEAR="2006"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="" MONTH="" YEAR=""/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="3" YEAR="2001"/>
<REVIEW_PUBLISHED ISSUE="2" YEAR="2006"/>
<LAST_CITATION_ISSUE ISSUE="2" YEAR="2006"/>
</DATES>
<WHATS_NEW MODIFIED="2008-07-18 12:04:49 +0100" MODIFIED_BY="[Empty name]">
<WHATS_NEW_ENTRY EVENT="STABLE" MODIFIED="2008-07-18 12:04:49 +0100" MODIFIED_BY="[Empty name]">
<DATE DAY="18" MONTH="7" YEAR="2008"/>
<DESCRIPTION>
<P>This review will not be updated because the four-dose regimen is no longer recommended. Only the six-dose regimen, reviewed in <LINK REF="REF-Omari-2005" TYPE="REFERENCE">Omari 2005</LINK>, is recommended (<LINK REF="REF-WHO-2007" TYPE="REFERENCE">WHO 2007</LINK>).</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2008-07-18 11:59:13 +0100" MODIFIED_BY="[Empty name]">
<DATE DAY="18" MONTH="7" YEAR="2008"/>
<DESCRIPTION>
<P>Converted to new review format with minor editing.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY MODIFIED="2008-07-17 14:13:26 +0100" MODIFIED_BY="[Empty name]">
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_NEW_CONCLUSIONS" MODIFIED="2008-07-17 14:08:28 +0100" MODIFIED_BY="[Empty name]">
<DATE DAY="12" MONTH="4" YEAR="2006"/>
<DESCRIPTION>
<P>2006, Issue 2: We have divided the original review into two separate reviews, one for the four-dose regimen (this review) and the other for the six-dose regimen (<LINK REF="REF-Omari-2005" TYPE="REFERENCE">Omari 2005</LINK>). We have excluded quasi-randomized controlled trials as the Cochrane Infectious Diseases Group no longer recommends their inclusion. The primary outcome measure has changed from 'parasitaemia on day 28' to 'total failure by day 28' to include any failures (clinical symptoms or parasitaemia) before this point and also anyone who is parasitaemic on day 28 when the blood slide is taken.<BR/>
</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT>
<INTERNAL_SOURCES>
<SOURCE>
<NAME>Liverpool School of Tropical Medicine</NAME>
<COUNTRY CODE="GB">UK</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</INTERNAL_SOURCES>
<EXTERNAL_SOURCES>
<SOURCE>
<NAME>Department for International Development</NAME>
<COUNTRY CODE="GB">UK</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</EXTERNAL_SOURCES>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2008-07-18 12:08:57 +0100" MODIFIED_BY="[Empty name]">
<SUMMARY>
<TITLE>Artemether-lumefantrine (four-dose regimen) for treating uncomplicated malaria</TITLE>
<SUMMARY_BODY>
<P>Malaria is a parasitic disease spread by mosquitoes. It affects millions of people worldwide and causes significant illness and mortality. Uncomplicated malaria presents with symptoms such as fever, headache, muscle pain, and vomiting. The parasite has become resistant to a number of previously effective drugs, and so combinations of drugs are used to try to prevent further resistance. Artemether-lumefantrine is one such drug combination. This review of trials showed that, although the four-dose artemether-lumefantrine regimen was superior to chloroquine, in general the four-dose regimen was less effective compared with the six-dose regimen or other drug combinations. The fact that the four-dose regimen is generally less effective means it is unlikely that it would be used for treating uncomplicated malaria.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2008-07-18 12:08:57 +0100" MODIFIED_BY="[Empty name]">
<ABS_BACKGROUND>
<P>The World Health Organization recommends artemether-lumefantrine, an expensive drug, as a treatment for uncomplicated malaria. We sought evidence of the superiority of the four-dose regimen over existing treatments.</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES>
<P>To evaluate the four-dose regimen of artemether-lumefantrine for treating uncomplicated falciparum malaria.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY>
<P>We searched the Cochrane Infectious Diseases Group Specialized Register (October 2005), CENTRAL (<I>The Cochrane Library</I> 2005, Issue 3), MEDLINE (1966 to October 2005), EMBASE (1988 to October 2005), LILACS (1982 to October 2005), conference proceedings, and reference lists of articles. We also contacted experts in malaria research and the pharmaceutical company that manufactures artemether-lumefantrine.</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA>
<P>Randomized controlled trials comparing four doses of artemether-lumefantrine with standard treatment regimens (single drug or combination), or six doses of artemether-lumefantrine, for treating uncomplicated falciparum malaria.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION>
<P>Two authors independently applied inclusion criteria to potentially relevant trials, assessed trial quality, and extracted data, including adverse events. Total failure by day 28 (day 42 for sulfadoxine-pyrimethamine and day 63 for mefloquine) was the primary outcome.</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS>
<P>Seven trials (2057 participants) tested a four-dose regimen. More people tended to fail treatment with artemether-lumefantrine than with other drugs, including sulfadoxine-pyrimethamine (247 participants, 1 trial), halofantrine (86 participants, 1 trial), and mefloquine (233 participants, 1 trial; difference statistically significant for mefloquine). When compared with chloroquine, artemether-lumefantrine was better in two trials (378 participants), but over 50% of the participants treated with chloroquine had total failure by day 28. Fewer people failed treatment with the six-dose regimen compared to the four-dose regimen (RR 7.71, 95% CI 2.99 to 19.88; 306 participants, 1 trial).</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS MODIFIED="2008-07-18 12:08:57 +0100" MODIFIED_BY="[Empty name]">
<P>The four-dose regimen of artemether-lumefantrine seems to be less effective than regimens against which it has been tested. The six-dose regimen is superior to four-dose regimen.</P>
<P>2008: This review will not be updated because the four-dose regimen is no longer recommended; see 'What's new' for details.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2008-07-18 12:05:48 +0100" MODIFIED_BY="[Empty name]">
<BACKGROUND MODIFIED="2008-07-16 14:31:07 +0100" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="2">Foreword</HEADING>
<P>Since the first Cochrane Review on artemether-lumefantrine was published (<LINK REF="REF-Omari-2002" TYPE="REFERENCE">Omari 2002</LINK>), the six-dose regimen treatment has become the standard, since the four-dose regimen is acknowledged to be associated with treatment failures (<LINK REF="REF-Nosten-2003" TYPE="REFERENCE">Nosten 2003</LINK>). Trials are generally using the six-dose regimen, and the evidence for this regimen is maintained in a separate review (<LINK REF="REF-Omari-2005" TYPE="REFERENCE">Omari 2005</LINK>). This review evaluates the four-dose regimen. We do not intend to update this review as the question has been answered.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="2">Malaria</HEADING>
<P>Malaria is a major health problem with at least 300 to 500 million people diagnosed with the illness every year (<LINK REF="REF-WHO-2000a" TYPE="REFERENCE">WHO 2000a</LINK>). The main cause is <I>Plasmodium falciparum</I>, one of the four species of malaria parasites found in humans. Uncomplicated malaria occurs in the majority of those affected, and is the form of the illness which presents with such symptoms as fever, headache, muscle pain (myalgia), vomiting, mild diarrhoea, anaemia, and enlarged spleen (splenomegaly). Children also commonly present with rapid breathing (tachypnoea), cough, and convulsions.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="2">Antimalarial drug resistance</HEADING>
<P>The resistance of malaria parasites to antimalarials emerged in South-East Asia and South America (<LINK REF="REF-White-1999a" TYPE="REFERENCE">White 1999a</LINK>), and then spread to Africa and western Oceania. Sulfadoxine-pyrimethamine has replaced chloroquine as the first-line treatment in some African countries (such as Malawi and Kenya), but resistance to this is also emerging (<LINK REF="REF-WHO-2000a" TYPE="REFERENCE">WHO 2000a</LINK>). Resistance to sulfadoxine-pyrimethamine is relatively common in South-East Asia (<LINK REF="REF-WHO-2001b" TYPE="REFERENCE">WHO 2001b</LINK>), where resistance and declining sensitivity to mefloquine have also been reported (<LINK REF="REF-WHO-2000a" TYPE="REFERENCE">WHO 2000a</LINK>). Mefloquine is contraindicated in areas of intensive malaria transmission, such as sub-Saharan Africa, because its long half life may expose parasites to subcurative doses that could result in the development of resistant strains (<LINK REF="REF-WHO-2000a" TYPE="REFERENCE">WHO 2000a</LINK>).</P>
<P>Artemisinin drugs, including artemether and artesunate, are now used as first-line treatments in some countries in South-East Asia, but they are recommended only as combination treatment (<LINK REF="REF-WHO-2000a" TYPE="REFERENCE">WHO 2000a</LINK>). Such combination therapy affords rapid clinical response and higher cure rates when compared with other antimalarial combinations (<LINK REF="REF-White-1999a" TYPE="REFERENCE">White 1999a</LINK>). Combination therapy may slow the development of resistance (<LINK REF="REF-White-1999b" TYPE="REFERENCE">White 1999b</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="2">Artemether-lumefantrine combination</HEADING>
<P>The fixed-dose combination of artemether-lumefantrine, called co-artemether, contains 20 mg of artemether and 120 mg of lumefantrine (previously called benflumetol). It was initially developed by scientists at the Academy of Military Medical Sciences in China before the pharmaceutical company Novartis (Switzerland) became a partner and was licensed to market it as Coartem® or Riamet®. This oral preparation is designed for use against chloroquine-resistant falciparum malaria. Artemether has a rapid onset of action and the short half life of two to three hours (Lefèvre 1999) means that it is rapidly eliminated from the plasma. Lumefantrine is cleared more slowly and has a longer elimination half life of about 4.5 days (<LINK REF="REF-Ezzet-1998" TYPE="REFERENCE">Ezzet 1998</LINK>). The rationale behind this combination is that artemether initially provides rapid symptomatic relief by reducing the number of parasites present before lumefantrine eliminates any residual parasites. This is thought to minimize development of resistance because the malaria parasites are never exposed to artemether alone (due to its rapid elimination). Although they may be exposed to lumefantrine alone, the probability of resistance developing simultaneously to both drugs used in combination is thought to be low (<LINK REF="REF-Bloland-2000" TYPE="REFERENCE">Bloland 2000</LINK>). Artemether-lumefantrine also reduces gametocyte carriage and thus should have an impact on malaria transmission (<LINK REF="REF-Van-Vugt-1998b" TYPE="REFERENCE">Van Vugt 1998b</LINK>).</P>
<P>There has been some concern about the possible risk of neurotoxicity with artemisinin derivatives arose from animal studies using high doses of lipid-soluble preparations given intramuscularly (<LINK REF="REF-WHO-1999" TYPE="REFERENCE">WHO 1999</LINK>). No serious adverse or persistent neurotoxic adverse events have been documented (<LINK REF="REF-Novartis-2005" TYPE="REFERENCE">Novartis 2005</LINK>). There has been concern that the lumefantrine component could have adverse cardiac effects due to its similar structure to halofantrine (<LINK REF="REF-Bindschedler-2000" TYPE="REFERENCE">Bindschedler 2000</LINK>). Artemether-lumefantrine causes minimal QTc prolongation, but it was not associated with adverse clinical cardiac events (<LINK REF="REF-Novartis-2005" TYPE="REFERENCE">Novartis 2005</LINK>). These potential adverse effects have to be considered when assessing the drug combination.</P>
<P>Artemether-lumefantrine has been added to the WHO Model List of Essential Medicines and is being promoted in Africa as first-line treatment for malaria by the World Health Organization. The World Health Organization has commended Novartis for providing the drug at discounted prices for developing countries in malaria endemic areas (<LINK REF="REF-WHO-2001a" TYPE="REFERENCE">WHO 2001a</LINK>).</P>
<P>This review aims to summarize the existing evidence of different doses of artemether-lumefantrine and how it compares with other antimalarial drugs for treating uncomplicated falciparum malaria, including mefloquine, sulfadoxine-pyrimethamine, and chloroquine.</P>
<P>For our primary outcome measure, we use total failure by day 28 as the primary outcome measure or day 42 for sulfadoxine-pyrimethamine and day 63 for mefloquine because of their long half lives. In areas where malaria transmission is intense, recurrence of parasites by day 28 could also be due to re-infection, so we also examine the polymerase chain reaction (PCR), which is thought to distinguish between a new infection and a recurrence of malaria (recrudescence) due to drug resistance.</P>
</SUBSECTION>
</BACKGROUND>
<OBJECTIVES>
<P>To evaluate the four-dose regimen of artemether-lumefantrine for treating uncomplicated falciparum malaria.</P>
</OBJECTIVES>
<METHODS MODIFIED="2008-07-17 14:16:57 +0100" MODIFIED_BY="[Empty name]">
<SELECTION_CRITERIA MODIFIED="2008-07-16 15:03:32 +0100" MODIFIED_BY="[Empty name]">
<CRIT_STUDIES>
<P>Randomized controlled trials.</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS>
<P>Adults and children with acute uncomplicated malaria, as defined in <LINK REF="REF-WHO-2000b" TYPE="REFERENCE">WHO 2000b</LINK>, with asexual <I>P. falciparum</I> parasitaemia confirmed from blood slides.</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS MODIFIED="2008-07-16 14:31:36 +0100" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="4">Intervention</HEADING>
<P>Four doses of artemether-lumefantrine.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Control</HEADING>
<UL>
<LI>Standard treatment regimens (single drug or combination).</LI>
<LI>Six doses of artemether-lumefantrine.</LI>
</UL>
</SUBSECTION>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2008-07-16 15:03:32 +0100" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="4">Primary</HEADING>
<P>Total failure by day 28, day 42 (for sulfadoxine-pyrimethamine), or day 63 (for mefloquine); defined as a recurrent malaria infection with or without clinical malaria.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Secondary</HEADING>
<UL>
<LI>Total failure adjusted by PCR to exclude new infections (recrudescent infections) by day 28.</LI>
<LI>Parasite clearance time (PCT), defined as the time between commencing treatment and the first negative blood test when negativity persists for more than 48 hours; PCT 50, defined as the time taken for parasites to be reduced to 50% of first test value; and PCT 90, defined as the time taken for parasites to be reduced to 10% of first test value.</LI>
<LI>Fever clearance time, defined as the time between starting treatment and the temperature returning back to normal, and remaining normal for more than 48 hours.</LI>
<LI>Gametocyte carriage on days 14 and 28.</LI>
<LI>Gametocyte clearance time, defined as the time taken for gametocytes to disappear (if present in the blood initially) after commencing treatment.</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Adverse events</HEADING>
<UL>
<LI>Adverse events requiring discontinuation of treatment or are fatal, life-threatening, or require hospitalization.</LI>
<LI>Other adverse events (all other adverse events).</LI>
</UL>
</SUBSECTION>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2008-07-16 15:04:30 +0100" MODIFIED_BY="[Empty name]">
<P>We attempted to identify all relevant trials regardless of language or publication status (published, unpublished, in press, and in progress).</P>
<SUBSECTION>
<HEADING LEVEL="3">Databases</HEADING>
<P>We searched the following databases using the search terms and strategy described in <LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK>: Cochrane Infectious Diseases Group Specialized Register (October 2005); Cochrane Central Register of Controlled Trials (CENTRAL), published in <I>The Cochrane Library</I> (2005, Issue 3); MEDLINE (1966 to October 2005); EMBASE (1974 to October 2005); and LILACS (1982 to October 2005).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Conference proceedings</HEADING>
<P>We searched the following conference proceedings for relevant abstracts: The Third Multilateral Initiative on Malaria Pan-African Conference, 18 to 22 November 2002, Arusha, Tanzania; and the Second European Congress on Tropical Medicine (Liverpool, UK, 14 to 18 September 1998).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Researchers, organizations, and pharmaceutical companies</HEADING>
<P>We contacted researchers working in the field, the World Health Organization, and the pharmaceutical company Novartis for unpublished and ongoing trials.</P>
</SUBSECTION>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2008-07-17 14:16:57 +0100" MODIFIED_BY="[Empty name]">
<STUDY_SELECTION MODIFIED="2008-07-16 11:31:58 +0100" MODIFIED_BY="[Empty name]">
<P>Aika Omari (AO) screened the results of the search strategy to identify potentially relevant trials. AO and Carrol Gamble (CG) independently assessed the eligibility of these trials for inclusion in the review using the stated inclusion criteria. Any differences in opinion between the authors were discussed with the third author (PG).</P>
</STUDY_SELECTION>
<DATA_EXTRACTION MODIFIED="2008-07-16 11:40:18 +0100" MODIFIED_BY="[Empty name]">
<P>AO and CG independently extracted data of trial characteristics including methods, participants, interventions, and outcomes, and recorded the data on standard forms. Where data from the published papers were insufficient or missing, we contacted the trial authors for additional information.</P>
<P>Where possible, we extracted data to allow an intention-to-treat analysis (the analysis should include all the participants in the groups to which they were originally randomly assigned). This approach is considered to be more pragmatic as it attempts to estimate the effectiveness of the treatment in routine practice rather than in the context of a clinical trial. To allow the intention-to-treat principle to be applied, all participants should be followed for the duration of the trial irrespective of whether or not the treatment course was completed or other protocol deviations. Any reason for dropping out of the trial or being excluded from the trial should be documented (<LINK REF="REF-WHO-1996" TYPE="REFERENCE">WHO 1996</LINK>).</P>
<P>If the number of participants randomized and the numbers analysed were inconsistent, we calculated the percentage loss to follow up. For dichotomous outcomes, we recorded the number of participants experiencing the event in each group of the trial. For continuous outcomes, we extracted arithmetic means and standard deviations and combined means using mean difference for each group where possible. If the data were reported using geometric means, we extracted standard deviations on the log scale, and extracted and reported the medians and ranges.</P>
</DATA_EXTRACTION>
<QUALITY_ASSESSMENT MODIFIED="2008-07-17 14:16:34 +0100" MODIFIED_BY="[Empty name]">
<P>We assessed the generation of allocation sequence and concealment of allocation as adequate, inadequate, or unclear according to <LINK REF="REF-J_x00fc_ni-2001" TYPE="REFERENCE">Jüni 2001</LINK>. We described whether the trial was open, single blind, or double blind. We assessed the inclusion of all randomized participants in the analysis of the reported primary outcome to be adequate if 90% or more were included in the analysis, inadequate if less than 90%, or unclear.</P>
</QUALITY_ASSESSMENT>
<DATA_SYNTHESIS MODIFIED="2008-07-17 14:16:57 +0100" MODIFIED_BY="[Empty name]">
<P>We analysed data using <LINK REF="REF-Review-Manager-5" TYPE="REFERENCE">Review Manager 5</LINK>. We compared outcome measures for dichotomous data using risk ratio (RR), which is the risk of achieving an outcome in the artemether-lumefantrine group relative to that in the control group, and 95% confidence intervals (CI). We used total failure (clinical or parasitological failure by day 28) as our main outcome, and we also conducted analysis excluding re-infection where PCR data were available. As the value of the risk ratio is constrained to lie between 0 and 1/CGER (control group event rate), large values of the risk ratio are impossible when events are common, so failure is preferred to treatment success.</P>
<P>For total failure with trials that had conducted PCR analysis, we classified the infections into: 1. recrudescent infection (matching genotypes on day 0 and day of recurrence); 2. new infection (different genotypes on day 0 and day of recurrence); and 3. missing values. We conducted an analysis of parasitaemia corrected for PCR on days 14 and 28. We intended to conduct a sensitivity analysis around PCR examining the effect of missing data, but there were too few trials for us to do this.</P>
<P>We intended to explore age, level of malaria transmission, and level of drug resistance as potential sources of heterogeneity, and to conduct sensitivity analyses according to blinding, allocation concealment, whether the trials used an intention-to-treat analysis, and total failure adjusted by PCR to exclude new infections, but data were insufficient.</P>
</DATA_SYNTHESIS>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2008-07-17 14:17:59 +0100" MODIFIED_BY="[Empty name]">
<STUDY_DESCRIPTION MODIFIED="2008-07-17 14:17:35 +0100" MODIFIED_BY="[Empty name]">
<P>We identified 30 potentially relevant studies. Seven trials (2057 participants) met the inclusion criteria (<I>see</I> '<LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK>'), with one trial, <LINK REF="STD-Hatz-1998" TYPE="STUDY">Hatz 1998</LINK>, reported across two publications. We excluded 19 studies for the reasons given in the '<LINK TAG="CHARACTERISTICS_OF_EXCLUDED_STUDIES" TYPE="SECTION">Characteristics of excluded studies</LINK>'. We have requested data since 2003 on four studies from Novartis (cited in <LINK REF="REF-Novartis-1999" TYPE="REFERENCE">Novartis 1999</LINK>) but have not yet received a response.<BR/>
</P>
<SUBSECTION>
<HEADING LEVEL="3">Trial location</HEADING>
<P>Trials were conducted in The Gambia (<LINK REF="STD-Von-Seidlein-1998" TYPE="STUDY">Von Seidlein 1998</LINK>), Tanzania (<LINK REF="STD-Hatz-1998" TYPE="STUDY">Hatz 1998</LINK>), India (<LINK REF="STD-Kshirsagar-2000" TYPE="STUDY">Kshirsagar 2000</LINK>), travellers from the Tropics returning to France and the Netherlands (<LINK REF="STD-Van-Agtmael-1999a" TYPE="STUDY">Van Agtmael 1999a</LINK>), and Thailand (<LINK REF="STD-Van-Vugt-1998a" TYPE="STUDY">Van Vugt 1998a</LINK>; <LINK REF="STD-Looareesuwan-1999" TYPE="STUDY">Looareesuwan 1999</LINK>; <LINK REF="STD-Van-Vugt-1999" TYPE="STUDY">Van Vugt 1999</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Trial funding</HEADING>
<P>Four trials reported that they were sponsored by Novartis (<LINK REF="STD-Van-Vugt-1998a" TYPE="STUDY">Van Vugt 1998a</LINK>; <LINK REF="STD-Von-Seidlein-1998" TYPE="STUDY">Von Seidlein 1998</LINK>; <LINK REF="STD-Looareesuwan-1999" TYPE="STUDY">Looareesuwan 1999</LINK>; <LINK REF="STD-Van-Vugt-1999" TYPE="STUDY">Van Vugt 1999</LINK>). The other three trials did not mention funding.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Participants</HEADING>
<P>Two trials included 547 children aged one to five years (<LINK REF="STD-Hatz-1998" TYPE="STUDY">Hatz 1998</LINK>; <LINK REF="STD-Von-Seidlein-1998" TYPE="STUDY">Von Seidlein 1998</LINK>), two trials included 976 adults and children (<LINK REF="STD-Van-Vugt-1998a" TYPE="STUDY">Van Vugt 1998a</LINK>; <LINK REF="STD-Van-Vugt-1999" TYPE="STUDY">Van Vugt 1999</LINK>), and three trials included 534 participants over 13 years of age (<LINK REF="STD-Looareesuwan-1999" TYPE="STUDY">Looareesuwan 1999</LINK>; <LINK REF="STD-Van-Agtmael-1999a" TYPE="STUDY">Van Agtmael 1999a</LINK>; <LINK REF="STD-Kshirsagar-2000" TYPE="STUDY">Kshirsagar 2000</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Interventions</HEADING>
<P>All trials gave the four doses of artemether-lumefantrine over 48 hours. Two trials compared it with chloroquine (<LINK REF="STD-Hatz-1998" TYPE="STUDY">Hatz 1998</LINK>; <LINK REF="STD-Kshirsagar-2000" TYPE="STUDY">Kshirsagar 2000</LINK>). Other comparisons were with sulfadoxine-pyrimethamine (<LINK REF="STD-Von-Seidlein-1998" TYPE="STUDY">Von Seidlein 1998</LINK>), mefloquine (<LINK REF="STD-Looareesuwan-1999" TYPE="STUDY">Looareesuwan 1999</LINK>), halofantrine (<LINK REF="STD-Van-Agtmael-1999a" TYPE="STUDY">Van Agtmael 1999a</LINK>), mefloquine plus artesunate (<LINK REF="STD-Van-Vugt-1998a" TYPE="STUDY">Van Vugt 1998a</LINK>), and two six-dose regimens of artemether-lumefantrine (<LINK REF="STD-Van-Vugt-1999" TYPE="STUDY">Van Vugt 1999</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Antimalarial drug resistance</HEADING>
<P>Multiple-drug resistance was reported for three trials conducted in Thailand; one trial specified resistance to chloroquine, mefloquine, amodiaquine, and sulfadoxine-pyrimethamine (<LINK REF="STD-Looareesuwan-1999" TYPE="STUDY">Looareesuwan 1999</LINK>). Chloroquine resistance was reported in the Tanzanian trial, which was located in Ifakara where 20% of <I>P. falciparum</I> strains were resistant in 1988 (<LINK REF="STD-Hatz-1998" TYPE="STUDY">Hatz 1998</LINK>). <LINK REF="STD-Kshirsagar-2000" TYPE="STUDY">Kshirsagar 2000</LINK>, which took place in Mumbai, India, was stopped early because the overall cure rate with chloroquine decreased to 50% due to a higher degree of chloroquine resistance present than expected; it was not clear from the trial report whether this was the result of a formal preplanned stopping rule. The Gambian trial, <LINK REF="STD-Von-Seidlein-1998" TYPE="STUDY">Von Seidlein 1998</LINK>, was conducted in an area of chloroquine resistance and less than 5% of the <I>P. falciparum</I> strains were resistant to sulfadoxine-pyrimethamine.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Outcome measures</HEADING>
<P>(See <LINK REF="TBL-02" TYPE="TABLE">Table 2</LINK>). Total failure by day 28 was the most frequently reported outcome (five of the seven studies). The results of PCR analyses used to exclude new infections were reported in five trials. Five trials reported on fever clearance times. Time to parasite clearance was reported in six trials: two trials reported it as a time-to-event analysis (<LINK REF="STD-Looareesuwan-1999" TYPE="STUDY">Looareesuwan 1999</LINK>; <LINK REF="STD-Van-Agtmael-1999a" TYPE="STUDY">Van Agtmael 1999a</LINK>); the other trials calculated the time to clearance on those participants in which the event occurred. Six trials reported on gametocyte carriage, and all seven trials reported adverse events.</P>
</SUBSECTION>
</STUDY_DESCRIPTION>
<STUDY_QUALITY MODIFIED="2008-07-17 14:17:59 +0100" MODIFIED_BY="[Empty name]">
<P>
<I>See </I>
<LINK REF="TBL-03" TYPE="TABLE">Table 3</LINK>
<I> for the quality assessment and the '</I>
<LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK>
<I>' for details.</I>
</P>
<SUBSECTION>
<HEADING LEVEL="3">Generation of allocation sequence</HEADING>
<P>All the trials were reported as randomized. Four trials reported adequate generation of the allocation sequence. The remaining three trials mentioned randomization, but they did not report the methods used to generate the allocation sequence.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Concealment of allocation</HEADING>
<P>Allocation concealment was adequate in the six trials that used a priori numbered or coded drug containers, central randomization, or sequentially numbered and sealed, opaque envelopes. One trial did not describe the method of allocation concealment (<LINK REF="STD-Van-Agtmael-1999a" TYPE="STUDY">Van Agtmael 1999a</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Blinding</HEADING>
<P>Four trials reported as double blind used the double dummy technique, while the other three trials were described as open. Three of the seven trials used adequate methods to generate the allocation sequence and conceal allocation, and used double blinding (<LINK REF="STD-Von-Seidlein-1998" TYPE="STUDY">Von Seidlein 1998</LINK>; <LINK REF="STD-Looareesuwan-1999" TYPE="STUDY">Looareesuwan 1999</LINK>; <LINK REF="STD-Kshirsagar-2000" TYPE="STUDY">Kshirsagar 2000</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Inclusion of randomized participants in the analysis</HEADING>
<P>None of seven trials had complete data for all participants randomized into the trial for the duration of follow up. This was partly because researchers stopped follow up after a participant withdrew. An intention-to-treat analysis was therefore not possible for the trial investigators or for this review because the necessary data were not collected. All trials gave results of analyses based on evaluable participants, that is, participants still on treatment at each time point. Five of the trials, however, also claimed to have reported cure rates as an 'intention-to-treat' analysis (<LINK REF="STD-Hatz-1998" TYPE="STUDY">Hatz 1998</LINK>; <LINK REF="STD-Von-Seidlein-1998" TYPE="STUDY">Von Seidlein 1998</LINK>; <LINK REF="STD-Van-Agtmael-1999a" TYPE="STUDY">Van Agtmael 1999a</LINK>; <LINK REF="STD-Van-Vugt-1999" TYPE="STUDY">Van Vugt 1999</LINK>; <LINK REF="STD-Kshirsagar-2000" TYPE="STUDY">Kshirsagar 2000</LINK>). These are not the results of an intention-to-treat analysis and differed from their analysis of evaluable participants by assuming that all participants withdrawn from treatment or lost to follow up still had parasitaemia at all remaining time points. At the end of follow up, the number of participants evaluable for the primary outcome was more than 90% in one trial (<LINK REF="STD-Looareesuwan-1999" TYPE="STUDY">Looareesuwan 1999</LINK>), 90% to 85% in two trials (<LINK REF="STD-Von-Seidlein-1998" TYPE="STUDY">Von Seidlein 1998</LINK>; <LINK REF="STD-Van-Vugt-1999" TYPE="STUDY">Van Vugt 1999</LINK>), and less than 85% in four trials (<LINK REF="STD-Hatz-1998" TYPE="STUDY">Hatz 1998</LINK>; <LINK REF="STD-Van-Vugt-1998a" TYPE="STUDY">Van Vugt 1998a</LINK>; <LINK REF="STD-Van-Agtmael-1999a" TYPE="STUDY">Van Agtmael 1999a</LINK>; <LINK REF="STD-Kshirsagar-2000" TYPE="STUDY">Kshirsagar 2000</LINK>).</P>
</SUBSECTION>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2008-07-16 15:09:41 +0100" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="3">1. Versus sulfadoxine-pyrimethamine (287 participants, 1 trial)</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">Total failure and parasite clearance time</HEADING>
<P>
<LINK REF="STD-Von-Seidlein-1998" TYPE="STUDY">Von Seidlein 1998</LINK>, which was conducted in The Gambia, did not report any results for total failure by day 28 or 42. By day 14, there was no statistically significant difference in the number of participants with parasites between the two groups, but numbers were small (247 participants, <LINK REF="CMP-001.01" TYPE="ANALYSIS">Analysis 1.1</LINK>). PCR results were available for six of the eight treatment failures in the artemether-lumefantrine group (all new infections), but no PCR results were available for the three treatment failures in the sulfadoxine-pyrimethamine group (<LINK REF="TBL-04" TYPE="TABLE">Table 4</LINK>). Adjusting for new infections (with missing samples or failed tests classified as treatment failures) on day 14 did not change the statistical significance, but it did change the direction of the effect (<LINK REF="CMP-001.02" TYPE="ANALYSIS">Analysis 1.2</LINK>). However, parasite clearance time was faster with artemether-lumefantrine compared with sulfadoxine-pyrimethamine (PCT 50 mean 11.6 h, 144 participants; mean 21.1 h, 143 participants), although the trial authors reported that this difference was statistically significant (P &lt; 0.0001, test not stated).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Gametocyte carriage</HEADING>
<P>By day four there were fewer participants carrying gametocytes in the artemether-lumefantrine group than in the sulfadoxine-pyrimethamine group (115 participants, <LINK REF="CMP-001.03" TYPE="ANALYSIS">Analysis 1.3</LINK>). A similar pattern was observed at day 15 (253 participants, <LINK REF="CMP-001.04" TYPE="ANALYSIS">Analysis 1.4</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Adverse events</HEADING>
<P>Severe adverse events reported by the trialists are documented in <LINK REF="TBL-09" TYPE="TABLE">Table 9</LINK>.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">2. Versus mefloquine (252 participants, 1 trial)</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">Total failure, and parasite, fever, and gametocyte clearance times</HEADING>
<P>
<LINK REF="STD-Looareesuwan-1999" TYPE="STUDY">Looareesuwan 1999</LINK> reported that total failure was higher with artemether-lumefantrine by day 28 (RR 1.74, 95% CI 1.08 to 2.80; 233 participants, <LINK REF="CMP-002.01" TYPE="ANALYSIS">Analysis 2.1</LINK>). However, parasite and fever clearance times were faster with artemether-lumefantrine (<LINK REF="TBL-05" TYPE="TABLE">Table 5</LINK> and <LINK REF="TBL-06" TYPE="TABLE">Table 6</LINK>). Gametocyte clearance was also faster with artemether-lumefantrine, but this was not statistically evident in the first 72 hours (252 participants, <LINK REF="CMP-002.02" TYPE="ANALYSIS">Analysis 2.2</LINK> and<I> </I>
<LINK REF="TBL-07" TYPE="TABLE">Table 7</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Adverse events</HEADING>
<P>The majority of adverse events reported were mild or moderate (<LINK REF="TBL-08" TYPE="TABLE">Table 8</LINK>), but there were reports of some severe adverse events (<LINK REF="TBL-09" TYPE="TABLE">Table 9</LINK>). In particular, cardiac monitoring was reported with no difference in the QTc interval between the treatment groups.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">3. Versus halofantrine (103 participants, 1 trial)</HEADING>
<P>The participants in <LINK REF="STD-Van-Agtmael-1999a" TYPE="STUDY">Van Agtmael 1999a</LINK> were travellers returning to France and the Netherlands from the tropics.</P>
<SUBSECTION>
<HEADING LEVEL="4">Total failure</HEADING>
<P>Although the number of participants failing treatment by day 28 was higher with artemether-lumefantrine, it was not statistically significant (86 participants, <LINK REF="CMP-003.01" TYPE="ANALYSIS">Analysis 3.1</LINK>). The wide confidence interval reflects considerable imprecision, therefore clinically important results cannot be excluded in either direction.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Parasite clearance time</HEADING>
<P>All participants on halofantrine cleared their parasites. The trial authors reported that parasite clearance time was statistically significant faster with artemether-lumefantrine (<LINK REF="TBL-05" TYPE="TABLE">Table 5</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Fever clearance time</HEADING>
<P>Fever clearance was faster with artemether-lumefantrine, but this was not statistically significant (<LINK REF="TBL-06" TYPE="TABLE">Table 6</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Gametocyte carriage</HEADING>
<P>There was no statistically significant difference between the two treatments within the first 72 hours (14 participants, <LINK REF="CMP-003.02" TYPE="ANALYSIS">Analysis 3.2</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Adverse events</HEADING>
<P>Most of the reported adverse events were mild or moderate (<LINK REF="TBL-08" TYPE="TABLE">Table 8</LINK>), but four separate severe adverse events were also documented (<LINK REF="TBL-09" TYPE="TABLE">Table 9</LINK>). Some of the occurrences resulted in stopping treatment. The results of cardiac monitoring showed a significant increase in the overall QTc interval in participants treated with halofantrine (26/52) compared with artemether-lumefantrine (8/51).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">4. Versus chloroquine (439 participants, 2 trials)</HEADING>
<P>
<LINK REF="STD-Kshirsagar-2000" TYPE="STUDY">Kshirsagar 2000</LINK>, a double blind trial, was conducted in an area of India with an unexpectedly high chloroquine resistance, which resulted in the trial being terminated before completion. <LINK REF="STD-Hatz-1998" TYPE="STUDY">Hatz 1998</LINK>, which was an open trial in Tanzania, was also conducted in an area of high levels of chloroquine resistance.</P>
<SUBSECTION>
<HEADING LEVEL="4">Total failure</HEADING>
<P>Both trials showed that artemether-lumefantrine was associated with fewer failures on day 28, but the size of this effect varied greatly between the two trials (<LINK REF="CMP-004.01" TYPE="ANALYSIS">Analysis 4.1</LINK>): <LINK REF="STD-Hatz-1998" TYPE="STUDY">Hatz 1998</LINK> reported a risk ratio of 0.38 (95% CI 0.30 to 0.49) with 237 participants, and <LINK REF="STD-Kshirsagar-2000" TYPE="STUDY">Kshirsagar 2000</LINK> reported a risk ratio of 0.06 (95% CI 0.02 to 0.17) with 141 participants. The significant heterogeneity could be attributed to age, transmission, or degree of chloroquine resistance. As there is no benefit of increased precision for this meta-analysis, it is more useful to consider the individual trial results. On days seven and 14, <LINK REF="STD-Hatz-1998" TYPE="STUDY">Hatz 1998</LINK> reported fewer parasitological failures with artemether-lumefantrine<I>.</I>
</P>
<P>The trial authors did PCR analyses on subsets of participants who failed treatment on days 14 and 28 (<LINK REF="TBL-04" TYPE="TABLE">Table 4</LINK>). Less than half of the treatment failures in <LINK REF="STD-Hatz-1998" TYPE="STUDY">Hatz 1998</LINK> were tested, so any statistical inferences must be made with extreme caution. In <LINK REF="STD-Kshirsagar-2000" TYPE="STUDY">Kshirsagar 2000</LINK>, all treatment failures in the artemether-lumefantrine group were classified as recrudescent infections although no PCR was done.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Parasite clearance time and fever clearance time</HEADING>
<P>
<LINK REF="STD-Kshirsagar-2000" TYPE="STUDY">Kshirsagar 2000</LINK> reported that parasite and fever clearance times were statistically significantly faster with artemether-lumefantrine (<LINK REF="TBL-05" TYPE="TABLE">Table 5</LINK> and <LINK REF="TBL-06" TYPE="TABLE">Table 6</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Gametocytes</HEADING>
<P>The pooled results from the two trials suggested a reduction in gametocyte carriage with artemether-lumefantrine within the first 72 hours (RR 0.79, 95% CI 0.63 to 0.99; 427 participants, <LINK REF="CMP-004.02" TYPE="ANALYSIS">Analysis 4.2</LINK>). Gametocyte clearance was faster with artemether-lumefantrine compared with chloroquine (<LINK REF="TBL-07" TYPE="TABLE">Table 7</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Adverse events</HEADING>
<P>Most reported adverse events were mild or moderate (<LINK REF="TBL-08" TYPE="TABLE">Table 8</LINK>), but a few were severe (<LINK REF="TBL-09" TYPE="TABLE">Table 9</LINK>). No deaths reported by either trial were associated with trial medication. <LINK REF="STD-Hatz-1998" TYPE="STUDY">Hatz 1998</LINK> reported occurrences of adverse events that resulted in stopping treatment. <LINK REF="STD-Kshirsagar-2000" TYPE="STUDY">Kshirsagar 2000</LINK> reported cardiac monitoring with no difference in the QTc interval between treatment groups. One participant on halofantrine was withdrawn from treatment due to a prolonged QTc interval.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">5. Versus mefloquine plus artesunate (617 participants, 1 trial)</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">Total failure</HEADING>
<P>
<LINK REF="STD-Van-Vugt-1998a" TYPE="STUDY">Van Vugt 1998a</LINK>, conducted in Thailand, reported that more participants experienced total failure with artemether-lumefantrine at day 28 than with mefloquine plus artesunate (RR 6.77, 95% CI 3.12 to 14.67; 537 participants, <LINK REF="CMP-005.01" TYPE="ANALYSIS">Analysis 5.1</LINK>). The results remained similar when new infections were excluded (RR 6.45, 95% CI 2.78 to 14.95; 537 participants, <LINK REF="CMP-005.02" TYPE="ANALYSIS">Analysis 5.2</LINK>). The total failure on day 63 was also higher with artemether-lumefantrine (RR 2.67, 95% CI 1.55 to 4.57; 478 participants, <LINK REF="CMP-005.03" TYPE="ANALYSIS">Analysis 5.3</LINK>).</P>
<P>PCR was conducted on 80% (72/89) of participants with parasites on day 63. There was a trend to fewer new infections in the artemether-lumefantrine group, but there were more also recrudescent infections in the artemether-lumefantrine group.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Parasite and fever clearance times</HEADING>
<P>The trial authors reported the median parasite clearance times in both groups as two days (range: one to three) and the median fever clearance time as one day (range: one to four) with no difference between the treatment groups.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Gametocyte carriage</HEADING>
<P>There was no statistically significant difference in gametocyte carriage within the first 72 hours between the two groups (RR 1.41, 95% CI 0.86 to 2.32; 616 participants, <LINK REF="CMP-005.04" TYPE="ANALYSIS">Analysis 5.4</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Adverse events</HEADING>
<P>
<LINK REF="STD-Van-Vugt-1998a" TYPE="STUDY">Van Vugt 1998a</LINK> specifically sought serious neurotoxicity, but it reported no such adverse event.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">6. Versus artemether-lumefantrine (six doses) (359 participants, 1 trial)</HEADING>
<P>
<LINK REF="STD-Van-Vugt-1999" TYPE="STUDY">Van Vugt 1999</LINK>, which was conducted in Thailand, compared the four-dose regimen of artemether-lumefantrine with two six-dose regimens given over 60 and 96 hours, respectively.</P>
<SUBSECTION>
<HEADING LEVEL="4">Total failure and parasite clearance time</HEADING>
<P>The four-dose regimen had higher parasitological failure rates at day 28 compared with six-dose regimen (RR 7.71, 95% CI 2.99 to 19.88; 60 hour and 96 hour regimens combined, 306 participants, <LINK REF="CMP-006.01" TYPE="ANALYSIS">Analysis 6.1</LINK>).</P>
<P>A PCR analysis was conducted during the 28-day follow up, but the results were reported according to the treatment site and not the treatment group. Twenty-four of the 25 treatment failures were evaluated by PCR genotyping. There were no re-infections in the 13 recurrent infections seen in the hospital, and four of the 11 recurrent malaria episodes at the campsite were new infections.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Parasite and fever clearance times</HEADING>
<P>The median parasite clearance time was 44 hours for all three groups (<LINK REF="TBL-05" TYPE="TABLE">Table 5</LINK>). There was no statistically significant difference in the median fever clearance times between the four-dose regimen and the two six-dose regimens (<LINK REF="TBL-06" TYPE="TABLE">Table 6</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Gametocytes</HEADING>
<P>For comparisons with the six-dose regimens, 66 (18.4%) of all the participants had gametocytes detected during the first 72 hours. Gametocyte carriage was reported according to treatment centre. There was no statistically significant difference in the gametocyte clearance time in comparisons between the four-dose and six-dose regimens (P = 0.5; trial authors' calculation).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Adverse events</HEADING>
<P>None were reported.</P>
</SUBSECTION>
</SUBSECTION>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION>
<P>Four of the seven trials described the methods used to generate the allocation sequence, and six trials described the concealment of allocation. Five trials reported an 'intention-to-treat' analysis for total failure, the primary outcome measure, but it was actually a limited form of sensitivity analysis because they made the assumption that all participants lost to follow up were treatment failures. As results were not based on an intention-to-treat analysis, they are subject to attrition bias and the clinical effectiveness may be biased. </P>
<P>Where PCR results were available, the total failure by day 14 and day 28 were corrected for new infections, with missing samples or failed tests classified as treatment failures. This did not materially affect the results for chloroquine and mefloquine plus artesunate, but it had a more substantial impact on sulfadoxine-pyrimethamine on day 14 by changing the direction of the effect to favour artemether-lumefantrine. </P>
<P>The four-dose regimen had significantly more treatment failures than the six-dose regimen. There was no significant difference in the parasite, fever, and gametocyte clearance times between the regimens, and the six-dose regimens were not associated with increased adverse events. The trial with the six-dose regimen as the comparator was conducted in an area with multiple-drug resistance, which is one of the recommendations for using this regimen. This review has shown that six-dose regimens are superior to the four-dose regimen in terms of total failure rates. </P>
<P>For parasitological outcomes, artemether-lumefantrine did not perform better than the other antimalarials apart from chloroquine. The trial comparing sulfadoxine-pyrimethamine with artemether-lumefantrine did not report on total failure on day 42. The fewer recrudescent and new infections seen in the sulfadoxine-pyrimethamine group may be explained by the long half life of sulfadoxine-pyrimethamine. Artemether-lumefantrine showed no marked advantage over mefloquine for parasitaemia in one trial of high quality (<LINK REF="STD-Looareesuwan-1999" TYPE="STUDY">Looareesuwan 1999</LINK>). Halofantrine had fewer treatment failures compared with artemether-lumefantrine, which was not statistically significant. However, this trial was small and the participants had varying degrees of immunity (they were from different countries), which could have confounded their response to medication (<LINK REF="REF-ter-Kuile-1995" TYPE="REFERENCE">ter Kuile 1995</LINK>). </P>
<P>Artemether-lumefantrine was only superior to chloroquine for total failure on day 28. However, there was a high withdrawal rate (more than 50% of the participants in the chloroquine group) in both trials, and the unexpected higher resistance to chloroquine decreased the cure rate to 50% in <LINK REF="STD-Kshirsagar-2000" TYPE="STUDY">Kshirsagar 2000</LINK>. This comparison would have been inappropriate had the actual chloroquine resistance been documented prior to commencing the trial since a clinical failure rate greater than 25% of a first-line antimalarial indicates the treatment should be changed (<LINK REF="REF-WHO-1994" TYPE="REFERENCE">WHO 1994</LINK>). </P>
<P>Parasite, fever, and gametocyte clearance times were shorter for artemether-lumefantrine when compared with the other antimalarial drugs, which suggests that clinical symptoms may resolve faster. With the exception of <LINK REF="STD-Looareesuwan-1999" TYPE="STUDY">Looareesuwan 1999</LINK> and <LINK REF="STD-Van-Agtmael-1999a" TYPE="STUDY">Van Agtmael 1999a</LINK>, the trials reported clearance times as medians and percentiles, and not as time-to-event analyses. Time-to-event analyses are more informative as data on participants who did not reach the event would have been included in the analysis. </P>
<P>It is important to acknowledge that the trials were not designed to evaluate safety. Although some trials reported adverse cardiac events, the evidence was insufficient to address concerns about the possible risk of cardiotoxicity. We, therefore, cannot justifiably comment on adverse events reported apart from reporting the details.</P>
</DISCUSSION>
<CONCLUSIONS MODIFIED="2008-07-18 12:05:48 +0100" MODIFIED_BY="[Empty name]">
<IMPLICATIONS_PRACTICE MODIFIED="2008-07-18 12:05:38 +0100" MODIFIED_BY="[Empty name]">
<P>Artemether-lumefantrine showed no advantage in relation to total failure when compared with mefloquine, mefloquine plus artesunate, halofantrine, and sulfadoxine-pyrimethamine (result not adjusted for new infections).</P>
<P>There is evidence to suggest the four-dose artemether-lumefantrine regimen is superior to chloroquine in areas where chloroquine resistance is common. In these circumstances, artemether-lumefantrine is an alternative to chloroquine as first-line treatment where policy makers wish to avoid sulfadoxine-pyrimethamine or other standard regimens.</P>
<P>The six-dose artemether-lumefantrine regimen is superior to the four-dose regimen.</P>
<P>2008: This review will not be updated because the four-dose regimen is no longer recommended. Only the six-dose regimen, reviewed in <LINK REF="REF-Omari-2005" TYPE="REFERENCE">Omari 2005</LINK>, is recommended (<LINK REF="REF-WHO-2007" TYPE="REFERENCE">WHO 2007</LINK>).</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH MODIFIED="2008-07-18 12:05:48 +0100" MODIFIED_BY="[Empty name]">
<P>Since the artemether-lumefantrine is no longer used as a four-dose regimen, there is no need for further research.</P>
<P>2008: This review will not be updated because the four-dose regimen is no longer recommended. Only the six-dose regimen, reviewed in <LINK REF="REF-Omari-2005" TYPE="REFERENCE">Omari 2005</LINK>, is recommended (<LINK REF="REF-WHO-2007" TYPE="REFERENCE">WHO 2007</LINK>).</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS>
<P>This document is an output from a project funded by the UK Department for International Development (DFID) for the benefit of developing countries. The views expressed are not necessarily those of DFID.</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST>
<P>Paul Garner and Carrol Gamble (né Preston) were unpaid technical advisers to a World Health Organization meeting (19 and 20 February 2001) considering efficacy and effectiveness studies of artemether-lumefantrine. The World Health Organization paid for their travel and accommodation, and a representative of Novartis chaired the international meeting.</P>
<P>Aika Omari: none known.</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS>
<P>Aika Omari and Carrol Gamble extracted and analysed data, and drafted the review. Paul Garner helped write the review.</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF MODIFIED="2008-07-17 14:22:30 +0100" MODIFIED_BY="[Empty name]"/>
<PUBLIC_NOTES/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2008-07-18 12:04:09 +0100" MODIFIED_BY="[Empty name]">
<STUDIES>
<INCLUDED_STUDIES>
<STUDY DATA_SOURCE="PUB" ID="STD-Hatz-1998" NAME="Hatz 1998" YEAR="1998">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Hatz C, Abdulla S, Mull R, Schellenberg D, Gathmann I, Kibatala P, et al</AU>
<TI>Efficacy and safety of CGP 56697 (artemether and benflumetol) compared with chloroquine to treat acute falciparum malaria in Tanzanian children aged 1-5 years</TI>
<SO>Tropical Medicine and International Health</SO>
<YR>1998</YR>
<VL>3</VL>
<NO>6</NO>
<PG>498-504</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Irion A, Felger I, Abdulla S, Smith T, Mull R, Tanner M, et al</AU>
<TI>Distinction of recrudescences from new infections by PCR-RFLP analysis in a comparative trial of CPG 56 697 and chloroquine in Tanzanian children</TI>
<SO>Tropical Medicine and International Health</SO>
<YR>1998</YR>
<VL>3</VL>
<NO>6</NO>
<PG>490-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kshirsagar-2000" NAME="Kshirsagar 2000" YEAR="2000">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kshirsagar N, Gogtay NJ, Moorthy NS, Garg MR, Dalvi SS, Chogle AR, et al</AU>
<TI>A randomized, double-blind, parallel-group, comparative safety, and efficacy trial of oral co-artemether versus oral chloroquine in the treatment of acute uncomplicated Plasmodium falciparum malaria in adults in India</TI>
<SO>American Journal of Tropical Medicine and Hygiene</SO>
<YR>2000</YR>
<VL>62</VL>
<NO>3</NO>
<PG>402-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Looareesuwan-1999" NAME="Looareesuwan 1999" YEAR="1999">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Looareesuwan S, Wilairatana P, Chokejindachai W, Chalermrut K, Wernsdorfer W, Gemperli B, et al</AU>
<TI>A randomized, double-blind, comparative trial of a new oral combination of artemether and benflumetol (CGP 56697) with mefloquine in the treatment of acute Plasmodium falciparum malaria in Thailand</TI>
<SO>American Journal of Tropical Medicine and Hygiene</SO>
<YR>1999</YR>
<VL>60</VL>
<NO>2</NO>
<PG>238-43</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Van-Agtmael-1999a" NAME="Van Agtmael 1999a" YEAR="1999">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Van Agtmael M, Bouchaud O, Malvy D, Delmont J, Danis M, Barette S, et al</AU>
<TI>The comparative efficacy and tolerability of CGP 56697 (artemether + lumefantrine) versus halofantrine in the treatment of uncomplicated falciparum malaria in travellers returning from the Tropics to The Netherlands and France</TI>
<SO>International Journal of Antimicrobial Agents</SO>
<YR>1999</YR>
<VL>12</VL>
<NO>2</NO>
<PG>159-69</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Van-Vugt-1998a" NAME="Van Vugt 1998a" YEAR="1998">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Van Vugt M, Brockman A, Gemperli B, Luxemburger C, Gathmann I, Royce C, et al</AU>
<TI>Randomized comparison of artemether-benflumetol and artesunate-mefloquine in treatment of multidrug-resistant falciparum malaria</TI>
<SO>Antimicrobial Agents and Chemotherapy</SO>
<YR>1998</YR>
<VL>42</VL>
<NO>1</NO>
<PG>135-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Van-Vugt-1999" NAME="Van Vugt 1999" YEAR="1999">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Van Vugt M, Wilairatana P, Gemperli B, Gathmann I, Phaipun L, Brockman A, et al</AU>
<TI>Efficacy of six doses of artemether-lumefantrine (benflumetol) in multidrug-resistant Plasmodium falciparum malaria</TI>
<SO>American Journal of Tropical Medicine and Hygiene</SO>
<YR>1999</YR>
<VL>60</VL>
<NO>6</NO>
<PG>936-42</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Von-Seidlein-1998" NAME="Von Seidlein 1998" YEAR="1998">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Von Seidlein, Bojang K, Jones P, Jaffar S, Pinder M, Obaro S, et al</AU>
<TI>A randomized controlled trial of artemether/benflumetol, a new antimalarial and pyrimethamine/sulfadoxine in the treatment of uncomplicated falciparum malaria in African children</TI>
<SO>American Journal of Tropical Medicine and Hygiene</SO>
<YR>1998</YR>
<VL>58</VL>
<NO>5</NO>
<PG>638-44</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES>
<STUDY DATA_SOURCE="UNPUB" ID="STD-Espino-2002" NAME="Espino 2002" YEAR="2002">
<REFERENCE PRIMARY="NO" TYPE="UNPUBLISHED">
<AU>Espino FE</AU>
<TI>Efficacy studies of chloroquine+sulfadoxine-pyrimethamine, sulfadoxine-pyrimethamine and artemether-lumefantrine for uncomplicated malaria in Mindanao Island, Philippines</TI>
<YR>2002</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Falade-2005" NAME="Falade 2005" YEAR="2005">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Falade C, Makanga M, Premji Z, Ortmann CE, Stockmeyer M, de Palacios PI</AU>
<TI>Efficacy and safety of artemether-lumefantrine (Coartem) tablets (six-dose regimen) in African infants and children with acute uncomplicated falciparum malaria</TI>
<SO>Transactions of the Royal Society of Tropical Medicine and Hygiene</SO>
<YR>2005</YR>
<VL>99</VL>
<NO>6</NO>
<PG>459-67</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="UNPUB" ID="STD-Jiao-1997" NAME="Jiao 1997" YEAR="1997">
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Jiao XQ, Liu EY, Shan CQ, Dal P, Gathmann I, Mull R, et al</AU>
<TI>A double-blind comparative trial of benflumetol, a novel antimalaria, and CGP 56697, a combination of benflumetol and artemether, in the treatment of acute P. falciparum malaria in adults in China</TI>
<SO>Proceedings of the 5th International Conference of Travel Medicine; 1997 Mar 24-27; Geneva (Switzerland)</SO>
<YR>1997</YR>
<PG>Abstract 108</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="UNPUB" ID="STD-Karbwang-2002" NAME="Karbwang 2002" YEAR="2002">
<REFERENCE PRIMARY="NO" TYPE="OTHER">
<AU>Karbwang J</AU>
<TI>Coartemether safety and efficacy evaluation of the six dose regimen in the treatment of uncomplicated malaria in children and infants</TI>
<YR>2002</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Krudsood-2003" NAME="Krudsood 2003" YEAR="2003">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Krudsood S, Chalermrut K, Pengruksa C, Srivilairit S, Silachamroon U, Treeprasertsuk S, et al</AU>
<TI>Comparative clinical trial of two-fixed combinations dihydroartemisinin-napthoquine-trimethoprim (DNP) and artemether-lumefantrine (Coartem/Riamet) in the treatment of acute uncomplicated falciparum malaria in Thailand</TI>
<SO>Southeast Asian Journal of Tropical Medicine and Public Health</SO>
<YR>2003</YR>
<VL>34</VL>
<NO>2</NO>
<PG>316-21</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lefevre-2001" NAME="Lefevre 2001" YEAR="2001">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lefevre G, Looareesuwan S, Treeprasertsuk S, Krudsood S, Silachamroon U, Gathmann I, et al</AU>
<TI>A clinical and pharmacokinetic trial of six doses of artemether-lumefantrine for multidrug-resistant Plasmodium falciparum malaria in Thailand</TI>
<SO>American Journal of Tropical Medicine and Hygiene</SO>
<YR>2001</YR>
<VL>64</VL>
<NO>5-6</NO>
<PG>247-56</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lefevre-2002" NAME="Lefevre 2002" YEAR="2002">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lefevre G, Carpenter P, Souppart C, Schmidli H, Martin JM, Lane A, et al</AU>
<TI>Interaction trial between artemether-lumefantrine (Riamet) and quinine in healthy subjects</TI>
<SO>Journal of Clinical Pharmacology</SO>
<YR>2002</YR>
<VL>42</VL>
<NO>10</NO>
<PG>1147-58</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mayxay-2004" NAME="Mayxay 2004" YEAR="2004">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mayxay M, Khanthavong M, Lindegardh N, Keola S, Barends M, Pongvongsa T, et al</AU>
<TI>Randomized comparison of chloroquine plus sulfadoxine-pyrimethamine versus artesunate plus mefloquine versus artemether-lumefantrine in the treatment of uncomplicated falciparum malaria in the Lao People's Democratic Republic</TI>
<SO>Clinical Infectious Diseases</SO>
<YR>2004</YR>
<VL>39</VL>
<NO>8</NO>
<PG>1139-47</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mutabingwa-2005" NAME="Mutabingwa 2005" YEAR="2005">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mutabingwa TK, Anthony D, Heller A, Hallett R, Ahmed J, Drakeley C, et al</AU>
<TI>Amodiaquine alone, amodiaquine+sulfadoxine-pyrimethamine, amodiaquine+artesunate, and artemether-lumefantrine for outpatient treatment of malaria in Tanzanian children: a four-arm randomised effectiveness trial</TI>
<SO>Lancet</SO>
<YR>2005</YR>
<VL>365</VL>
<NO>9469</NO>
<PG>1474-80</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ndayiragije-2004" NAME="Ndayiragije 2004" YEAR="2004">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ndayiragije A, Niyungeko D, Karenzo J, Niyungeko E, Barutwanayo M, Ciza A, et al</AU>
<TI>Efficacy of therapeutic combinations with artemisinin derivatives in the treatment of non complicated malaria in Burundi</TI>
<TO>Efficacité de combinaisons thérapeutiques avec des dérivés de l'artémisinine dans le traitement de l'accès palustre non-complique au Burundi</TO>
<SO>Tropical Medicine &amp; International Health</SO>
<YR>2004</YR>
<VL>9</VL>
<NO>6</NO>
<PG>673-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Piola-2005" NAME="Piola 2005" YEAR="2005">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Piola P, Fogg C, Bajunirwe F, Biraro S, Grandesso F, Ruzagira E, et al</AU>
<TI>Supervised versus unsupervised intake of six-dose artemether-lumefantrine for treatment of acute, uncomplicated Plasmodium falciparum malaria in Mbarara, Uganda: a randomised trial</TI>
<SO>Lancet</SO>
<YR>2005</YR>
<VL>365</VL>
<NO>9469</NO>
<PG>1467-73</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Popov-2002" NAME="Popov 2002" YEAR="2002">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Popov AF, Morokov VS, Chirkov VP, Popova NI, Lama N</AU>
<TI>Efficacy of mefloquine, halofantrine, and coarteme in the treatment of tropical malaria</TI>
<SO>Meditsinskaia Parazitologiia i Parazitarnye Bolezni</SO>
<YR>2002</YR>
<VL>Jan-Mar</VL>
<NO>1</NO>
<PG>28-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Stohrer-2004" NAME="Stohrer 2004" YEAR="2004">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Stohrer JM, Dittrich S, Thongpaseuth V, Vanisaveth V, Phetsouvanh R, Phompida S, et al</AU>
<TI>Therapeutic efficacy of artemether-lumefantrine and artesunate-mefloquine for treatment of uncomplicated Plasmodium falciparum malaria in Luang Namtha Province, Lao People's Democratic Republic</TI>
<SO>Tropical Medicine &amp; International Health</SO>
<YR>2004</YR>
<VL>9</VL>
<NO>11</NO>
<PG>1175-83</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sun-2000" NAME="Sun 2000" YEAR="2000">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sun ZW, Shan CQ, Li GF, Ding DB, Liu GY, Wang JY, et al</AU>
<TI>Clinical comparative trial of co-artemether and benflumetol (two formulations) in the treatment of falciparum malaria</TI>
<SO>Zhongguo Ji Sheng Chong Xue Yu Ji Sheng Chong Bing Za Zhi [Chinese Journal of Parasitology &amp; Parasitic Diseases]</SO>
<YR>2000</YR>
<VL>18</VL>
<NO>3</NO>
<PG>159-61</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sutherland-2005" NAME="Sutherland 2005" YEAR="2005">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sutherland CJ, Ord R, Dunyo S, Jawara M, Drakeley CJ, Alexander N, et al</AU>
<TI>Reduction of malaria transmission to anopheles mosquitoes with a six-dose regimen of co-artemether</TI>
<SO>PLoS Medicine</SO>
<YR>2005</YR>
<VL>2</VL>
<NO>4</NO>
<PG>338-49</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Van-Agtmael-1999b" NAME="Van Agtmael 1999b" YEAR="1999">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Van Agtmael MA, Cheng-Qi S, Qing JX, Mull R, van Boxtel CJ</AU>
<TI>Multiple dose pharmacokinetics of artemether in Chinese patients with uncomplicated falciparum malaria</TI>
<SO>International Journal of Antimicrobial Agents</SO>
<YR>1999</YR>
<VL>12</VL>
<NO>2</NO>
<PG>151-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Van-Vugt-2000" NAME="Van Vugt 2000" YEAR="2000">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Van Vugt M, Ezzet F, Nosten F, Gathmann I, Wilairatana P, Looareesuwan S, et al</AU>
<TI>No evidence of cardiotoxicity during antimalarial treatment with artemether-lumefantrine</TI>
<SO>American Journal of Tropical Medicine and Hygiene</SO>
<YR>1999</YR>
<VL>61</VL>
<NO>6</NO>
<PG>964-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Van Vugt M, Looareesuwan S, Wilairatana P, McGready R, Villegas L, Gathmann I, et al</AU>
<TI>Artemether-lumefantrine for the treatment of multidrug-resistant falciparum malaria</TI>
<SO>Transactions of the Royal Society of Tropical Medicine and Hygiene</SO>
<YR>2000</YR>
<VL>94</VL>
<NO>5</NO>
<PG>545-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Von-Seidlein-1997" NAME="Von Seidlein 1997" YEAR="1997">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Von Seidlein L, Jaffer S, Pinder M , Haywood M, Snounou G, Gemperli B, et al</AU>
<TI>Treatment of African children with uncomplicated falciparum malaria with a new antimalarial drug, CGP 56697</TI>
<SO>Journal of Infectious Diseases</SO>
<YR>1997</YR>
<VL>176</VL>
<NO>4</NO>
<PG>1113-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Zhiwei-1999" NAME="Zhiwei 1999" YEAR="1999">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Zhiwei S, Chengqi S, Guofu L, Jingyan W, Deben D, Guangyu L, et al</AU>
<TI>Treatment effects of Co-artemether and Benflumetol capsule in naturally occuring falciparum malaria patients</TI>
<SO>Journal of Practical Parasitic Diseases</SO>
<YR>1999</YR>
<VL>7</VL>
<NO>2</NO>
<PG>49-51</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES/>
<ONGOING_STUDIES/>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2008-07-18 12:04:09 +0100" MODIFIED_BY="[Empty name]">
<ADDITIONAL_REFERENCES MODIFIED="2008-07-18 12:04:09 +0100" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-Bindschedler-2000" NAME="Bindschedler 2000" TYPE="JOURNAL_ARTICLE">
<AU>Bindschedler M, Lefevre G, Ezzet F, Schaffer N, Meyer I, Thomsen MS</AU>
<TI>Cardiac effects of co-artemether (artemether/lumefantrine) and mefloquine given alone or in combination to healthy volunteers</TI>
<SO>European Journal of Clinical Pharmacology</SO>
<YR>2000</YR>
<VL>56</VL>
<NO>5</NO>
<PG>375-81</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Bloland-2000" NAME="Bloland 2000" TYPE="JOURNAL_ARTICLE">
<AU>Bloland PB, Ettling M, Meek S</AU>
<TI>Combination therapy for malaria in Africa: hype or hope?</TI>
<SO>Bulletin of the World Health Organization</SO>
<YR>2000</YR>
<VL>78</VL>
<NO>12</NO>
<PG>1378-88</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Ezzet-1998" NAME="Ezzet 1998" TYPE="JOURNAL_ARTICLE">
<AU>Ezzet F, Mull R, Karbwang J</AU>
<TI>Population pharmacokinetics and therapeutic response of CGP 56697 (artemether + benflumetol) in malaria patients</TI>
<SO>British Journal of Clinical Pharmacology</SO>
<YR>1998</YR>
<VL>46</VL>
<NO>6</NO>
<PG>553-61</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2005" NAME="Higgins 2005" TYPE="OTHER">
<AU>Higgins J, Green S, editors</AU>
<TI>Highly sensitive search strategies for identifying reports of randomized controlled trials in MEDLINE. Cochrane Handbook for Systematic Reviews of Interventions 4.2.5 [updated May 2005]; Appendix 5b</TI>
<SO>http://www.cochrane.org/resources/handbook/hbook.htm</SO>
<YR>(accessed 1 October 2005)</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-J_x00fc_ni-2001" MODIFIED="2008-07-17 14:16:34 +0100" MODIFIED_BY="[Empty name]" NAME="Jüni 2001" TYPE="JOURNAL_ARTICLE">
<AU>Jüni P, Altman DG, Egger M</AU>
<TI>Systematic reviews in health care: Assessing the quality of controlled clinical trials</TI>
<SO>BMJ</SO>
<YR>2001</YR>
<VL>323</VL>
<NO>7303</NO>
<PG>42-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Nosten-2003" NAME="Nosten 2003" TYPE="JOURNAL_ARTICLE">
<AU>Nosten F</AU>
<TI>Letters to the Editor</TI>
<SO>The Newsletter of the East African Network for Monitoring Antimalarial Treatment</SO>
<YR>2003</YR>
<VL>6</VL>
<NO>1</NO>
<PG>10</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Novartis-1999" NAME="Novartis 1999" TYPE="BOOK">
<AU>Novartis</AU>
<SO>A novel antimalarial combination: one product, two concepts Coartem / Riamet. Product monograph</SO>
<YR>1999</YR>
<PB>Novartis Pharma AG</PB>
<CY>Basel, Switzerland</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Novartis-2005" NAME="Novartis 2005" TYPE="BOOK">
<AU>Novartis</AU>
<SO>Coartem monograph</SO>
<YR>2005</YR>
<EN>4th</EN>
<PB>Novartis Pharma AG</PB>
<CY>Basel</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Omari-2005" MODIFIED="2008-07-16 14:46:16 +0100" MODIFIED_BY="[Empty name]" NAME="Omari 2005" TYPE="COCHRANE_REVIEW">
<AU>Omari AAA, Gamble C, Garner P</AU>
<TI>Artemether-lumefantrine (six doses) for treating uncomplicated falciparum malaria</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2005</YR>
<NO>4</NO>
<IDENTIFIERS MODIFIED="2008-07-16 14:46:16 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2008-07-16 14:46:16 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD005564 "/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Review-Manager-5" MODIFIED="2008-07-17 14:17:06 +0100" MODIFIED_BY="[Empty name]" NAME="Review Manager 5" TYPE="COMPUTER_PROGRAM">
<TI>Review Manager (RevMan)</TI>
<YR>2008</YR>
<EN>5.0</EN>
<PB>The Nordic Cochrane Centre, The Cochrane Collaboration</PB>
<CY>Copenhagen</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-ter-Kuile-1995" NAME="ter Kuile 1995" TYPE="JOURNAL_ARTICLE">
<AU>ter Kuile FO, Luxemburger C, Nosten F, Thwai KL, Chongsuphajaisiddhi T, White NJ</AU>
<TI>Predictors of mefloquine treatment failure: a prospective study of 1590 patients with uncomplicated falciparum malaria</TI>
<SO>Transactions of the Royal Society of Medicine and Hygiene</SO>
<YR>1995</YR>
<VL>89</VL>
<NO>6</NO>
<PG>660-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Van-Vugt-1998b" NAME="Van Vugt 1998b" TYPE="CONFERENCE_PROC">
<AU>Van Vugt M, Nosten F, Price RN, Looareesuwan S, White NJ</AU>
<TI>Antimalarial drug resistance: Treatment and prevention</TI>
<SO>Proceedings of the Second European Congress on Tropical Medicine. 1998 Sept 14-18; Liverpool (UK)</SO>
<YR>1998</YR>
<PG>Abstract 463</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-White-1999a" NAME="White 1999a" TYPE="JOURNAL_ARTICLE">
<AU>White N</AU>
<TI>Antimalarial drug resistance and combination chemotherapy</TI>
<SO>Philosophical Transactions of the Royal Society of London Series B, Biological Sciences</SO>
<YR>1999</YR>
<VL>354</VL>
<NO>1384</NO>
<PG>739-49</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-White-1999b" NAME="White 1999b" TYPE="JOURNAL_ARTICLE">
<AU>White NJ, Nosten F, Looareesuwan S, Watkins WM, Marsh K, Snow RW, et al</AU>
<TI>Averting a malaria disaster</TI>
<SO>Lancet</SO>
<YR>1999</YR>
<VL>353</VL>
<NO>9168</NO>
<PG>1965-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-WHO-1994" NAME="WHO 1994" TYPE="BOOK">
<AU>World Health Organization. Division of Control of Tropical Diseases</AU>
<SO>Antimalarial drug policies: data requirements, treatment of uncomplicated malaria and management of malaria in pregnancy. Report of an informal consultation, Geneva, 14-18 March 1994</SO>
<YR>1994</YR>
<PB>World Health Organization</PB>
<CY>Geneva</CY>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="WHO/MAL/94.1070"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-WHO-1996" NAME="WHO 1996" TYPE="BOOK">
<AU>World Health Organization. Division of Control of Tropical Diseases</AU>
<SO>Assessment of therapeutic efficacy of antimalarial drugs: for uncomplicated falciparum malaria in areas with intense transmission</SO>
<YR>1996</YR>
<PB>World Health Organization</PB>
<CY>Geneva</CY>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="WHO/MAL/96.1077"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-WHO-1999" NAME="WHO 1999" TYPE="BOOK">
<AU>World Health Organization. Department of Communicable Disease Research and Development</AU>
<SO>WHO informal consultation on clinical neurological investigations required for patients treated with artemisinin compounds and derivatives. Report of an informal consultation convened by WHO, Geneva, 20 July 1998</SO>
<YR>1998</YR>
<PB>World Health Organization</PB>
<CY>Geneva</CY>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="TDR/TDF/99.1"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-WHO-2000a" NAME="WHO 2000a" TYPE="OTHER">
<AU>World Health Organization. WHO Expert Committee on Malaria (1998 : Geneva, Switzerland)</AU>
<TI>WHO expert committee on malaria: twentieth report</TI>
<SO>World Health Organization Technical Report Series</SO>
<YR>2000</YR>
<VL>892</VL>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-WHO-2000b" NAME="WHO 2000b" TYPE="JOURNAL_ARTICLE">
<AU>World Health Organization. Communicable Diseases Cluster</AU>
<TI>Severe falciparum malaria</TI>
<SO>Transactions of the Royal Society of Tropical Medicine and Hygiene</SO>
<YR>2000</YR>
<VL>94</VL>
<NO>Suppl 1</NO>
<PG>1-90</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-WHO-2001a" NAME="WHO 2001a" TYPE="OTHER">
<AU>World Health Organization. Office of Press and Public Relations</AU>
<TI>WHO and Novartis join forces to combat drug resistant malaria</TI>
<SO>http://www.who.int/inf-pr-2001/en/pr2001-26.html</SO>
<YR>(accessed 23 May 2001)</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-WHO-2001b" NAME="WHO 2001b" TYPE="BOOK">
<AU>World Health Organization. Global Partnership to Roll Back Malaria</AU>
<SO>The use of antimalarial drugs. Report of a WHO informal consultation, 13-17 November 2000</SO>
<YR>2001</YR>
<PB>World Health Organization</PB>
<CY>Geneva</CY>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="WHO/CDS/RBM/2001.33"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-WHO-2007" MODIFIED="2008-07-18 12:04:09 +0100" MODIFIED_BY="[Empty name]" NAME="WHO 2007" TYPE="OTHER">
<AU>World Health Organization</AU>
<TI>WHO Essential Medicines Library: artemether + lumefantrine</TI>
<SO>www.who.int/emlib/</SO>
<YR>March 2007 (accessed 18 July 2008)</YR>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES MODIFIED="2008-07-16 14:44:12 +0100" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-Omari-2002" MODIFIED="2008-07-16 14:44:00 +0100" MODIFIED_BY="[Empty name]" NAME="Omari 2002" TYPE="COCHRANE_REVIEW">
<AU>Omari AAA, Gamble C, Garner P</AU>
<TI>Artemether-lumefantrine for treating uncomplicated falciparum malaria</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2002</YR>
<NO>3</NO>
<IDENTIFIERS MODIFIED="2008-07-16 14:44:00 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2008-07-16 14:44:00 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD003125.pub2"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Omari-2003" MODIFIED="2008-07-16 14:44:12 +0100" MODIFIED_BY="[Empty name]" NAME="Omari 2003" TYPE="COCHRANE_REVIEW">
<AU>Omari AAA, Gamble C, Garner P</AU>
<TI>Artemether-lumefantrine for treating uncomplicated falciparum malaria</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2003</YR>
<NO>2</NO>
<IDENTIFIERS MODIFIED="2008-07-16 14:44:12 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2008-07-16 14:44:12 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD003125.pub2"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Omari-2004" NAME="Omari 2004" TYPE="JOURNAL_ARTICLE">
<AU>Omari AAA Gamble C, Garner P</AU>
<TI>Artemether-lumefantrine for uncomplicated malaria: a systematic review</TI>
<SO>Tropical Medicine &amp; International Health</SO>
<YR>2004</YR>
<VL>9</VL>
<NO>2</NO>
<PG>192-9</PG>
<IDENTIFIERS/>
</REFERENCE>
</OTHER_VERSIONS_REFERENCES>
<PENDING_REFERENCES/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2008-07-17 14:23:44 +0100" MODIFIED_BY="[Empty name]">
<CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2008-07-17 14:23:44 +0100" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR MODIFIED="2008-07-17 14:22:40 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Hatz-1998">
<CHAR_METHODS MODIFIED="2008-07-16 11:52:15 +0100" MODIFIED_BY="[Empty name]">
<P>Generation of allocation sequence: not described</P>
<P>Allocation concealment: concealed allocation, numbered blister packs</P>
<P>Blinding: none</P>
<P>Inclusion of all randomized participants in the analysis of reported primary outcome: 45% (118/260)</P>
<P>Number of blocks used in randomization: 6</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-07-17 14:22:40 +0100" MODIFIED_BY="[Empty name]">
<P>Number: 260 children aged 1 to 5 years</P>
<P>Inclusion criteria: weight &gt; 5 kg; microscopically confirmed <I>P. falciparum</I> parasitaemia &gt; 5000/mL; fever; within 5 km of trial site</P>
<P>Exclusion criteria: severe malaria; severe malnutrition/kwashiorkor; other antimalarial previous in 48 h; sensitivity to chloroquine; chronic disease</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-07-16 11:54:24 +0100" MODIFIED_BY="[Empty name]">
<P>1. Artemether-lumefantrine: 4 doses over 48 h; artemether 1 to 2 mg/kg/dose; lumefantrine 6 to 12 mg/kg/dose<BR/>2. Chloroquine: 4 doses over 48 h; total dose 25 mg/kg</P>
<P>All participants had paracetamol</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-07-16 11:54:50 +0100" MODIFIED_BY="[Empty name]">
<P>1. Day 7 cure<BR/>2. Day 14 cure<BR/>3. Parasite reductions on days 1 to 3<BR/>4. Proportion of children with negative slide on days 1 to 3<BR/>5. PCR genotype<BR/>6. Gametocyte carriage on days 0, 1, 2, 3, and 7<BR/>7. Haemoglobin</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-07-16 11:53:45 +0100" MODIFIED_BY="[Empty name]">
<P>Location: Ifakara, Tanzania</P>
<P>48 not evaluable at day 7 (14 artemether-lumefantrine, 34 chloroquine); 53 not evaluable at day 14 (20 artemether-lumefantrine, 33 chloroquine)</P>
<P>Malaria transmission: perennial</P>
<P>Chloroquine resistance</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-07-17 14:23:02 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kshirsagar-2000">
<CHAR_METHODS MODIFIED="2008-07-16 11:57:08 +0100" MODIFIED_BY="[Empty name]">
<P>Generation of allocation sequence: computer-generated</P>
<P>Allocation concealment: concealed allocation, central randomization</P>
<P>Blinding: double dummy parallel, blinding not specified</P>
<P>Inclusion of all randomized participants in the analysis of reported primary outcome: 21% (38/179)</P>
<P>Number of blocks used in randomization: 4</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-07-17 14:23:02 +0100" MODIFIED_BY="[Empty name]">
<P>Number: 179 adults aged 16 to 70 years</P>
<P>Inclusion criteria: microscopically confirmed <I>P. falciparum</I> or mixed infection (including <I>P. falciparum</I> &gt; 1000/µL)</P>
<P>Exclusion criteria: <I>P. falciparum</I> &gt; 200,000/µL; severe malaria</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-07-16 12:04:46 +0100" MODIFIED_BY="[Empty name]">
<P>1. Artemether-lumefantrine: 4 doses over 48 h; artemether 80 mg/dose; lumefantrine 480 mg/dose<BR/>2. Chloroquine: 4 doses over 48 h; first dose 600 mg, then 300 mg per dose</P>
<P>All had primaquine on day 8 (single dose of 45 mg)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-07-16 11:58:20 +0100" MODIFIED_BY="[Empty name]">
<P>1. Day 28 cure<BR/>2. Parasite clearance time<BR/>3. Reduction in parasite load at 24 h<BR/>4. Fever clearance time<BR/>5. Gametocyte carriage within first 72 h<BR/>6. Gametocyte clearance time<BR/>7. PCR genotype<BR/>8. Adverse events</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-07-16 11:57:40 +0100" MODIFIED_BY="[Empty name]">
<P>Location: Mumbai, India</P>
<P>Participants hospitalized for 8 days</P>
<P>38 not evaluated on day 28: 24 (artemether-lumefantrine); 14 (chloroquine)</P>
<P>64 treatment failures: 3 artemether-lumefantrine (RI); 61 chloroquine (49 (RI), 8 (RII), 4 (RIII))</P>
<P>Premature termination of trial because of 1 death (chloroquine group) and decrease in chloroquine cure rate to &lt; 50%</P>
<P>Malaria transmission: perennial</P>
<P>Chloroquine resistance</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-07-17 14:23:08 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Looareesuwan-1999">
<CHAR_METHODS MODIFIED="2008-07-16 11:58:56 +0100" MODIFIED_BY="[Empty name]">
<P>Generation of allocation sequence: computer-generated</P>
<P>Allocation concealment: concealed allocation, central randomization</P>
<P>Blinding: double dummy, participants and all personnel</P>
<P>Inclusion of all randomized participants in the analysis of reported primary outcome: 8% (19/252)</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-07-17 14:23:08 +0100" MODIFIED_BY="[Empty name]">
<P>Number: 252 adults and children aged 13 to 63</P>
<P>Inclusion criteria: microscopically confirmed <I>P. falciparum</I>; parasitaemia 1000 to 200,000/µL (mixed infection acceptable)</P>
<P>Exclusion criteria: complicated malaria</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-07-16 11:59:31 +0100" MODIFIED_BY="[Empty name]">
<P>1. Artemether-lumefantrine: 4 doses over 48 h; artemether 80 mg/dose; lumefantrine 480 mg/dose<BR/>2. Mefloquine: 2 doses over 8 h; first dose 750 mg; second dose 500 mg</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-07-16 11:59:51 +0100" MODIFIED_BY="[Empty name]">
<P>1. Day 28 cure<BR/>2. Parasite clearance time<BR/>3. Fever clearance time<BR/>4. Gametocyte clearance time<BR/>5. Gametocyte carriage within first 72 h<BR/>6. Adverse effects</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-07-16 11:59:19 +0100" MODIFIED_BY="[Empty name]">
<P>Location: Bangkok, Thailand</P>
<P>Inpatients</P>
<P>19 not evaluated on day 28: 12 (artemether-lumefantrine); 7 (mefloquine)</P>
<P>56 treatment failures: 35 artemether-lumefantrine (RI); 21 mefloquine (12 (RI), 5 (RII), 4 (RIII))</P>
<P>Malaria transmission: low transmission</P>
<P>Multiple-drug resistance</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-07-17 14:23:18 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Van-Agtmael-1999a">
<CHAR_METHODS MODIFIED="2008-07-16 12:00:15 +0100" MODIFIED_BY="[Empty name]">
<P>Generation of allocation sequence: computer-generated</P>
<P>Allocation concealment: not described</P>
<P>Blinding: double dummy, participants and all personnel</P>
<P>Inclusion of all randomized participants in the analysis of reported primary outcome: 17% (17/103)</P>
<P>Number of blocks used in randomization: 4</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-07-17 14:23:18 +0100" MODIFIED_BY="[Empty name]">
<P>Number: 103 participants aged 17 to 62 (73 non-immune; 3 immune; 27 possibly immune)</P>
<P>Inclusion criteria: microscopically confirmed <I>P. falciparum</I> (&gt; 1000 and &lt; 200,000/µL)</P>
<P>Exclusion criteria: severe malaria</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-07-16 12:00:58 +0100" MODIFIED_BY="[Empty name]">
<P>1. Artemether-lumefantrine: 4 doses over 48 h; artemether 80 mg/dose; lumefantrine 480 mg/dose<BR/>2. Halofantrine: 3 doses over 12 h; repeated after 1 week; 500 mg/dose</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-07-16 12:01:18 +0100" MODIFIED_BY="[Empty name]">
<P>1. Day 28 cure<BR/>2. Parasite clearance time<BR/>3. Parasite reduction at 24 h<BR/>4. Fever clearance time<BR/>5. Gametocyte carriage within first 72 h<BR/>6. Adverse effects<BR/>7. QT interval</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-07-16 12:00:51 +0100" MODIFIED_BY="[Empty name]">
<P>Location: residents of France and the Netherlands returning from 22 African countries and French Guyana</P>
<P>17 not evaluable on day 28: 6 (artemether-lumefantrine); 11 (halofantrine)</P>
<P>8 treatment failures: artemether-lumefantrine 8 (RI)</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-07-16 12:02:34 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Van-Vugt-1998a">
<CHAR_METHODS MODIFIED="2008-07-16 12:01:34 +0100" MODIFIED_BY="[Empty name]">
<P>Generation of allocation sequence: not described</P>
<P>Allocation concealment: concealed allocation, numbered sealed opaque packets</P>
<P>Blinding: none</P>
<P>Inclusion of all randomized participants in the analysis of reported primary outcome: 23% (139/617)</P>
<P>Number of blocks used in randomization: 4</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-07-16 12:01:41 +0100" MODIFIED_BY="[Empty name]">
<P>Number: 617 participants aged 5 to 66 years</P>
<P>Inclusion criteria: microscopically confirmed malaria</P>
<P>Exclusion criteria: severe malaria</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-07-16 12:02:12 +0100" MODIFIED_BY="[Empty name]">
<P>1. Artemether-lumefantrine: 4 doses over 48 h; artemether 1 to 2 mg/kg/dose; lumefantrine 6 to 12 mg/kg/dose<BR/>2. Artesunate: 3 doses over 48 h (4 mg/kg/dose); mefloquine 2 doses over 48 h (15 mg/kg on day 2; 10 mg/kg on day 3)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-07-16 12:02:34 +0100" MODIFIED_BY="[Empty name]">
<P>1. Day 63 cure<BR/>2. Day 28 cure<BR/>3. Parasite clearance time<BR/>4. Fever clearance time<BR/>5. Gametocyte carriage<BR/>6. PCR analysis<BR/>7. Adverse effects</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-07-16 12:01:51 +0100" MODIFIED_BY="[Empty name]">
<P>Location: Karen, Thailand</P>
<P>139 not evaluated on day 63: 61(artemether-lumefantrine); 78 (artemether plus mefloquine)</P>
<P>Malaria transmission: low</P>
<P>Multiple-drug resistance</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-07-17 14:23:25 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Van-Vugt-1999">
<CHAR_METHODS MODIFIED="2008-07-16 12:02:56 +0100" MODIFIED_BY="[Empty name]">
<P>Generation of allocation sequence: not described</P>
<P>Allocation concealment: concealed allocation, numbered sealed opaque packets</P>
<P>Blinding: none</P>
<P>Inclusion of all randomized participants in the analysis of reported primary outcome: 15% (53/359)</P>
<P>Number of blocks used in randomization: 6</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-07-17 14:23:25 +0100" MODIFIED_BY="[Empty name]">
<P>Number: 359 adults and children age 3 to 75</P>
<P>Inclusion criteria: microscopically confirmed <I>P. falciparum</I>
</P>
<P>Exclusion criteria: severe malaria, children &lt; 2 years</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-07-16 12:04:04 +0100" MODIFIED_BY="[Empty name]">
<P>1. Artemether-lumefantrine: 4 doses over 48 h<BR/>2. Artemether-lumefantrine: 6 doses over 60 h<BR/>3. Artemether-lumefantrine: 6 doses over 90 h</P>
<P>Single dose: 4 tablets for 15 kg; 8 tablets for 15 to 25 kg; 12 tablets for 25 to 35 kg; 16 tablets if &gt; 35 kg</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-07-16 12:04:26 +0100" MODIFIED_BY="[Empty name]">
<P>1. Day 28 cure<BR/>2. Parasite clearance time<BR/>3. PCR analysis<BR/>4. Adverse effects<BR/>5. Fever clearance time<BR/>6. Gametocyte carriage</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-07-16 12:03:42 +0100" MODIFIED_BY="[Empty name]">
<P>Location: Thailand</P>
<P>2 trial centres: Bangkok (inpatients for 28 days); Karen (outpatients)<BR/>Multiple-drug resistance</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-07-16 12:06:14 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Von-Seidlein-1998">
<CHAR_METHODS MODIFIED="2008-07-16 12:05:26 +0100" MODIFIED_BY="[Empty name]">
<P>Generation of allocation sequence: computer-generated</P>
<P>Allocation concealment: concealed allocation, central randomization</P>
<P>Blinding: double dummy, participants and all personnel</P>
<P>Inclusion of all randomized participants in the analysis of reported primary outcome: 14% (40/287)</P>
<P>Number of blocks used in randomization: 4</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-07-16 12:05:33 +0100" MODIFIED_BY="[Empty name]">
<P>Number: 287 children aged 1 to 5 years</P>
<P>Inclusion criteria: parasitaemia &gt; 5000/µL; fever; within 10 km of trial centre</P>
<P>Exclusion criteria: requiring parenteral treatment</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-07-16 12:05:51 +0100" MODIFIED_BY="[Empty name]">
<P>1. Artemether-lumefantrine: 4 doses over 48 h; artemether 1.3 to 2.6 mg/kg/dose; lumefantrine 8.8 to 17.5 mg/kg/dose)<BR/>2. Sulfadoxine-pyrimethamine: single dose; 8.8 to 17.5 mg/kg</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-07-16 12:06:14 +0100" MODIFIED_BY="[Empty name]">
<P>1. Day 4 cure<BR/>2. Day 15 cure<BR/>3. Parasite clearance time<BR/>4. Proportion of children with fever on days 1 to 4<BR/>5. Gametocyte carriage on days 1, 2, 3, 4, and 15<BR/>6. PCR genotype</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-07-16 12:05:43 +0100" MODIFIED_BY="[Empty name]">
<P>Location: The Gambia</P>
<P>2 trial centres: semi-urban and rural</P>
<P>40 not evaluated on day 28: 25 (artemether-lumefantrine); 15 (sulfadoxine-pyrimethamine)</P>
<P>Local malaria transmission: seasonal</P>
<P>Local drug resistance: chloroquine; sulfadoxine-pyrimethamine</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<FOOTNOTES>
<P>ECG: electrocardiogram; <I>P. falciparum</I>: <I>Plasmodium falciparum</I>; PCR: polymerase chain reaction; QT interval: difference between the longest and shortest measurable interval on the 12 lead electrocardiogram; RI: (drug resistance) recrudescence of infection between 7 and 28 d of completing treatment following initial resolution of symptoms and parasite clearance; RII: (drug resistance) reduction of parasitaemia of &gt; 75% at 48 h but failure to clear parasites within 7 d; RIII: (drug resistance) parasitaemia does not fall by &gt; 75% within 48 h.</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES SORT_BY="STUDY">
<EXCLUDED_CHAR STUDY_ID="STD-Espino-2002">
<CHAR_REASON_FOR_EXCLUSION>
<P>Data in unpublished report are not interpretable</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Falade-2005">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not a randomized controlled trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Jiao-1997">
<CHAR_REASON_FOR_EXCLUSION>
<P>Compared artemether-lumefantrine with lumefantrine, which is not a recommended standard therapy for uncomplicated malaria</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Karbwang-2002">
<CHAR_REASON_FOR_EXCLUSION>
<P>Artemether-lumefantrine (6-dose regimen) not compared with another antimalarial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Krudsood-2003">
<CHAR_REASON_FOR_EXCLUSION>
<P>Used 6-dose artemether-lumefantrine regimen</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Lefevre-2001">
<CHAR_REASON_FOR_EXCLUSION>
<P>Used 6-dose artemether-lumefantrine regimen</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Lefevre-2002">
<CHAR_REASON_FOR_EXCLUSION>
<P>Investigated electrocardiographic and pharmacokinetic interactions between artemether-lumefantrine and quinine</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Mayxay-2004">
<CHAR_REASON_FOR_EXCLUSION>
<P>Used 6-dose artemether-lumefantrine regimen</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Mutabingwa-2005">
<CHAR_REASON_FOR_EXCLUSION>
<P>Used 6-dose artemether-lumefantrine regimen</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Ndayiragije-2004">
<CHAR_REASON_FOR_EXCLUSION>
<P>Used 6-dose artemether-lumefantrine regimen</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Piola-2005">
<CHAR_REASON_FOR_EXCLUSION>
<P>Used 6-dose artemether-lumefantrine regimen</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Popov-2002">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not a randomized controlled trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Stohrer-2004">
<CHAR_REASON_FOR_EXCLUSION>
<P>Used 6-dose artemether-lumefantrine regimen</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Sun-2000">
<CHAR_REASON_FOR_EXCLUSION>
<P>Compared artemether-lumefantrine with lumefantrine, which is not a recommended standard therapy for uncomplicated malaria</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Sutherland-2005">
<CHAR_REASON_FOR_EXCLUSION>
<P>Used 6-dose artemether-lumefantrine regimen</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Van-Agtmael-1999b">
<CHAR_REASON_FOR_EXCLUSION>
<P>Compared artemether</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Van-Vugt-2000">
<CHAR_REASON_FOR_EXCLUSION>
<P>Used 6-dose artemether-lumefantrine regimen</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Von-Seidlein-1997">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not randomized control trial (safety trial)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Zhiwei-1999">
<CHAR_REASON_FOR_EXCLUSION>
<P>Compared artemether-lumefantrine with lumefantrine, which is not a recommended standard therapy for uncomplicated malaria</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS MODIFIED="2008-07-16 11:56:09 +0100" MODIFIED_BY="[Empty name]">
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" NO="1">
<NAME>Adequate sequence generation?</NAME>
<DESCRIPTION>
<P>Was the allocation sequence adequately generated?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" MODIFIED="2008-07-16 11:56:09 +0100" MODIFIED_BY="[Empty name]" NO="2">
<NAME>Allocation concealment?</NAME>
<DESCRIPTION>
<P>Was allocation adequately concealed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" NO="3">
<NAME>Blinding?</NAME>
<DESCRIPTION>
<P>Was knowledge of the allocated interventions adequately prevented during the study?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" NO="4">
<NAME>Incomplete outcome data addressed?</NAME>
<DESCRIPTION>
<P>Were incomplete outcome data adequately addressed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" NO="5">
<NAME>Free of selective reporting?</NAME>
<DESCRIPTION>
<P>Are reports of the study free of suggestion of selective outcome reporting?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" NO="6">
<NAME>Free of other bias?</NAME>
<DESCRIPTION>
<P>Was the study apparently free of other problems that could put it at a high risk of bias?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES/>
<ADDITIONAL_TABLES MODIFIED="2008-07-17 14:30:35 +0100" MODIFIED_BY="[Empty name]">
<ADDITIONAL_TABLE ID="TBL-01" MODIFIED="2008-07-17 14:24:58 +0100" MODIFIED_BY="[Empty name]" NO="1">
<TITLE>Detailed search strategies</TITLE>
<TABLE COLS="6" ROWS="15">
<TR>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>Search set</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>CIDG SR*</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>CENTRAL</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>MEDLINE**</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>EMBASE<SUP>a</SUP>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>LILACS<SUP>b</SUP>
</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>artemether</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>artemether</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>artemether</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>artemether</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>artemether</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>2</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>lumefantrine</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>lumefantrine</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>lumefantrine</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>lumefantrine</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>lumefantrine</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>3</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>benflumetol</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>benflumetol</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>benflumetol</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>benflumetol</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>benflumetol</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>4</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>co-artemether</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>co-artemether</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>co-artemether</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>coartemether</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>co-artemether</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>5</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>coartem</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>coartem</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>coartem</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>coartem</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>coartem</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>6</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>coarteme</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>coarteme</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>coarteme</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>coarteme</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1 or 2 or 3 or 4 or 5</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>7</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>riamet</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>riamet</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>riamet</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>riamet</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>malaria</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>8</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>CGP56697</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>CGP56697</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>CGP56697</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>CGP56697</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>6 and 7</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>9</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8212;</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1 or 2 or 3 or 4 or 5 or 6 or 7 or 8</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1 or 2 or 3 or 4 or 5 or 6 or 7 or 8</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1 or 2 or 3 or 4 or 5 or 6 or 7 or 8</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8212;</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>10</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8212;</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>malaria</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>exp MALARIA</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>exp MALARIA</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8212;</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>11</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8212;</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>9 and 10</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>malaria</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>malaria</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8212;</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>12</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8212;</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8212;</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>10 or 11</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>10 or 11</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8212;</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>13</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8212;</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8212;</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>9 and 12</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>9 and 12</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8212;</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>14</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8212;</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8212;</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Limit 13 to human</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Limit 13 to human</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8212;</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>
<SUP>a</SUP>Cochrane Infectious Diseases Group Specialized Register.<BR/>
<SUP>b</SUP>Search terms used in combination with the search strategy for retrieving trials developed by The Cochrane Collaboration (<LINK REF="REF-Higgins-2005" TYPE="REFERENCE">Higgins 2005</LINK>); upper case: MeSH or EMTREE heading; lower case: free text term.</P>
</FOOTNOTES>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-02" MODIFIED="2008-07-16 14:49:53 +0100" MODIFIED_BY="[Empty name]" NO="2">
<TITLE>Reported outcome measures</TITLE>
<TABLE COLS="8" ROWS="8">
<TR>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>Trial</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>Total failure (day)</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>PCT</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>FCT</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>GCT</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>Gametocyte carriage</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>PCR analysis</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>Adverse events</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="STD-Hatz-1998" TYPE="STUDY">Hatz 1998</LINK>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>7 and 14</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>No</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>No</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>No</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Yes</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Yes</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Yes</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="STD-Van-Vugt-1998a" TYPE="STUDY">Van Vugt 1998a</LINK>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>28 and 63</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Yes</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Yes</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>No</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Yes</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Yes</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Yes</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="STD-Von-Seidlein-1998" TYPE="STUDY">Von Seidlein 1998</LINK>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>4 and 15</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Yes</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>No</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>No</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Yes</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Yes</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Yes</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="STD-Looareesuwan-1999" TYPE="STUDY">Looareesuwan 1999</LINK>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>28</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Yes</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Yes</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Yes</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Yes</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>No</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Yes</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="STD-Van-Agtmael-1999a" TYPE="STUDY">Van Agtmael 1999a</LINK>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>28</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Yes</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Yes</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>No</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Yes</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>No</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Yes</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="STD-Van-Vugt-1999" TYPE="STUDY">Van Vugt 1999</LINK>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>28</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Yes</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Yes</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>No</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Yes</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Yes</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Yes</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="STD-Kshirsagar-2000" TYPE="STUDY">Kshirsagar 2000</LINK>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>28</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Yes</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Yes</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Yes</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>No</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Yes</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Yes</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>FCT: fever clearance time; GCT: gametocyte clearance time; PCR: polymerase chain reaction; PCT: parasite clearance time.</P>
</FOOTNOTES>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-03" MODIFIED="2008-07-17 14:27:03 +0100" MODIFIED_BY="[Empty name]" NO="3">
<TITLE MODIFIED="2008-07-17 14:26:34 +0100" MODIFIED_BY="[Empty name]">Risk of bias assessment</TITLE>
<TABLE COLS="5" ROWS="8">
<TR>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>Trial</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>Generation of allocation sequence</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>Allocation concealment</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>Blinding</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>Inclusion of all randomized participant in the analysis<SUP>a</SUP>
</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="STD-Hatz-1998" TYPE="STUDY">Hatz 1998</LINK>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Not described</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Adequate</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>No</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Inadequate (45%)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="STD-Von-Seidlein-1998" TYPE="STUDY">Von Seidlein 1998</LINK>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Adequate</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Adequate</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Double</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Inadequate (86%)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="STD-Van-Vugt-1998a" TYPE="STUDY">Van Vugt 1998a</LINK>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Not described</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Adequate</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>No</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Inadequate (77%)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="STD-Looareesuwan-1999" TYPE="STUDY">Looareesuwan 1999</LINK>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Adequate</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Adequate</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Double</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Adequate (92%)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="STD-Van-Agtmael-1999a" TYPE="STUDY">Van Agtmael 1999a</LINK>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Adequate</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Not described</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Double</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Inadequate (83%)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="STD-Van-Vugt-1999" TYPE="STUDY">Van Vugt 1999</LINK>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Not described</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Adequate</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>No</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Inadequate (85%)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="STD-Kshirsagar-2000" TYPE="STUDY">Kshirsagar 2000</LINK>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Adequate</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Adequate</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Double</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Inadequate (79%)</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>
<SUP>a</SUP>For primary outcomes. see the '<LINK TAG="DATA_COLLECTION" TYPE="SECTION">Data collection and analysis</LINK>' for the assessment methods, and the '<LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK>' for each trial's methods.</P>
</FOOTNOTES>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-04" MODIFIED="2008-07-17 14:28:50 +0100" MODIFIED_BY="[Empty name]" NO="4">
<TITLE>Total failure (excludes new infections)</TITLE>
<TABLE COLS="7" ROWS="21">
<TR>
<TH ALIGN="LEFT" ROWSPAN="2" VALIGN="BOTTOM">
<P>Trial</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="2" VALIGN="BOTTOM">
<P>Comparator</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="2" VALIGN="BOTTOM">
<P>Measure</P>
</TH>
<TH ALIGN="CENTER" COLSPAN="2" VALIGN="BOTTOM">
<P>Day 14</P>
</TH>
<TH ALIGN="CENTER" COLSPAN="2" VALIGN="BOTTOM">
<P>Day 28</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>Artemether-lumefantrine</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>Comparator</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>Artemether-lumefantrine</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>Comparator</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="7" VALIGN="TOP">
<P>
<LINK REF="STD-Hatz-1998" TYPE="STUDY">Hatz 1998</LINK>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="7" VALIGN="TOP">
<P>Chloroquine</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Number participants failing treatment/number followed up</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>18/113</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>106/116</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>43/118</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>113/119</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Number with PCR tests/number total failures</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>7/18</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>52/106</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>23/43</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>44/113</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Missing sample of failed test</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Number of recrudescent infections</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>2</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>20</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>3</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>17</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Number with a new infection</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>4</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>5</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>12</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>6</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Number with new and recrudescent infections</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>27</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>7</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>20</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Corrected failure rate</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>14/113</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>101/116</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>31/118</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>107/119</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="6" VALIGN="TOP">
<P>
<LINK REF="STD-Von-Seidlein-1998" TYPE="STUDY">Von Seidlein 1998</LINK>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="6" VALIGN="TOP">
<P>Sulfadoxine-pyrimethamine</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Number participants failing treatment/number followed up</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>8/119</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>3/128</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>20/no data</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1/no data</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Number with PCR tests/number total failures</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>6/8</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0/3</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>16/20</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1/1</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Missing sample of failed test</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>2</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>3</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>4</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Number of recrudescent infections</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>No results</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>4</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Number with a new infection</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>6</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>No results</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>12</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Corrected failure rate</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>2/119</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>3/128</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>8/no data</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0/no data</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="6" VALIGN="TOP">
<P>
<LINK REF="STD-Kshirsagar-2000" TYPE="STUDY">Kshirsagar 2000</LINK>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="6" VALIGN="TOP">
<P>Chloroquine</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Number participants failing treatment/number followed up</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8212;</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8212;</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>3/65</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>61/76</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Number with PCR tests/number total failures</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8212;</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8212;</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0/3</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>42/61</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Missing sample of failed test</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8212;</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8212;</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>3</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Number of recrudescent infections</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8212;</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8212;</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>40</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>New infections</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8212;</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8212;</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>2</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Corrected day 28 failure rate</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8212;</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8212;</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>3/65</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>59/76</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-05" MODIFIED="2008-07-17 14:30:02 +0100" MODIFIED_BY="[Empty name]" NO="5">
<TITLE>Parasite clearance time</TITLE>
<TABLE COLS="7" ROWS="10">
<TR>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>Trial</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>Treatment</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>No. participants</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>Median</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>25 to 75 percentile</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>95% CI</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>P value</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>
<LINK REF="STD-Looareesuwan-1999" TYPE="STUDY">Looareesuwan 1999</LINK>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Artemether-lumefantrine</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>126</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>43</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>35 to 51</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>42 to 45</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&lt; 0.001<SUP>a</SUP>
</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Mefloquine</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>126</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>66</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>52 to 82</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>61 to 70</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8212;</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>
<LINK REF="STD-Van-Agtmael-1999a" TYPE="STUDY">Van Agtmael 1999a</LINK>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Artemether-lumefantrine</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>51</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>32</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>23 to 48</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>32 to 48</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&lt; 0.001</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Halofantrine</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>52</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>48</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>47 to 60</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>48 to 60</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8212;</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>
<LINK REF="STD-Van-Vugt-1999" TYPE="STUDY">Van Vugt 1999</LINK>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Artemether-lumefantrine (4 doses)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>120</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>44</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>34 to 51</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8212;</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0.96</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Artemether-lumefantrine (6 doses over 60 h)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>118</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>44</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>22 to 47</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8212;</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8212;</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Artemether-lumefantrine (6 doses over 90 h)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>121</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>44</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>40 to 47</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8212;</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8212;</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>
<LINK REF="STD-Kshirsagar-2000" TYPE="STUDY">Kshirsagar 2000</LINK>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Artemether-lumefantrine</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>89</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>36</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>24 to 48</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>30 to 36</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&lt; 0.001<SUP>a</SUP>
</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Chloroquine</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>90</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>60</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>48 to 91</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>45 to 66</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8212;</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>CI: confidence interval.<BR/>
<SUP>a</SUP>Wilcoxon test.<BR/>
</P>
</FOOTNOTES>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-06" MODIFIED="2008-07-17 14:29:54 +0100" MODIFIED_BY="[Empty name]" NO="6">
<TITLE>Fever clearance time</TITLE>
<TABLE COLS="7" ROWS="10">
<TR>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>Trial</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>Treatment</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>No. participants</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>Median</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>25 to 75 percentile</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>95% CI</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>P value</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>
<LINK REF="STD-Looareesuwan-1999" TYPE="STUDY">Looareesuwan 1999</LINK>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Artemether-lumefantrine</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>75</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>32</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>17 to 54</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>23 to 37</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0.003<SUP>a</SUP>
</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Mefloquine</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>67</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>54</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>29 to 82</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>36 to 66</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8212;</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>
<LINK REF="STD-Van-Agtmael-1999a" TYPE="STUDY">Van Agtmael 1999a</LINK>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Artemether-lumefantrine</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>32</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>24</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>12 to 48</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>18 to 42</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0.835</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Halofantrine</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>39</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>32</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>6 to 64</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>18 to 48</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8212;</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>
<LINK REF="STD-Van-Vugt-1999" TYPE="STUDY">Van Vugt 1999</LINK>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Artemether-lumefantrine (4 doses)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>61</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>23</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>20 to 44</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8212;</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0.38</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Artemether-lumefantrine (6 doses over 60 h)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>59</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>35</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>20 to 46</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8212;</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8212;</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Artemether-lumefantrine (6 doses over 90 h)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>80</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>22</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>20 to 44</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8212;</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8212;</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>
<LINK REF="STD-Kshirsagar-2000" TYPE="STUDY">Kshirsagar 2000</LINK>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Artemether-lumefantrine</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>40</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>18</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>6 to 30</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>12 to 29</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0.0456<SUP>a</SUP>
</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Chloroquine</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>54</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>27</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>12 to 48</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>18 to 36</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8212;</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>CI: confidence interval.<BR/>
<SUP>a</SUP>Wilcoxon test.<BR/>
</P>
</FOOTNOTES>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-07" MODIFIED="2008-07-17 14:30:04 +0100" MODIFIED_BY="[Empty name]" NO="7">
<TITLE>Gametocyte clearance time</TITLE>
<TABLE COLS="7" ROWS="5">
<TR>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>Trial</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>Treatment</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>No. participants</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>Median</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>25 to 75 percentile</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>95% CI</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>P value</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>
<LINK REF="STD-Looareesuwan-1999" TYPE="STUDY">Looareesuwan 1999</LINK>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Artemether-lumefantrine</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>62</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>152</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>68 to 285</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>89 to 185</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&lt; 0.001</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Mefloquine</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>74</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>331</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>128 to 512</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>281 to 492</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8212;</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>
<LINK REF="STD-Kshirsagar-2000" TYPE="STUDY">Kshirsagar 2000</LINK>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Artemether-lumefantrine</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>51</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>120</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>60 to not reached</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8212;</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&lt; 0.001<SUP>a</SUP>
</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Chloroquine</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>63</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Not reached</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8212;</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8212;</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8212;</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>CI: confidence interval.<BR/>
<SUP>a</SUP>Wilcoxon test.<BR/>
</P>
</FOOTNOTES>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-08" MODIFIED="2008-07-17 14:30:21 +0100" MODIFIED_BY="[Empty name]" NO="8">
<TITLE>Mild to moderate adverse events</TITLE>
<TABLE COLS="5" ROWS="16">
<TR>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>Comparator</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>Trial</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>Adverse event</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>Artemether-lumefantrine (%)<SUP>a</SUP>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>Comparator (%)<SUP>a</SUP>
</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="9" VALIGN="TOP">
<P>Chloroquine</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>
<LINK REF="STD-Hatz-1998" TYPE="STUDY">Hatz 1998</LINK>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Rashes</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>5/130 (3.8)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>5/130 (3.8)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Pruritis</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1/130 (0.8)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>8/130 (6.2)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Sleep disorders</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>50/130 (39.0)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>48/130 (37.0)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="6" VALIGN="TOP">
<P>
<LINK REF="STD-Kshirsagar-2000" TYPE="STUDY">Kshirsagar 2000</LINK>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Pruritis</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>2/89 (2.2)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>11/90 (12.2)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Vomiting</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1/89 (1.1)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>14/90 (15.3)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Headache</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>5/89 (5.6)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>7/90 (7.8)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Diarrhoea</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>4/89 (9.5)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>7/90 (7.8)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Sleep disorders</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>3/89 (3.4)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>2/90 (2.2)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Abdominal pain</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>10/89 (11.2)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>10/90 (11.1)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>Mefloquine</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>
<LINK REF="STD-Looareesuwan-1999" TYPE="STUDY">Looareesuwan 1999</LINK>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Vomiting</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1/126 (0.8)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>8/126 (6.3)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Headache</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>11/126 (8.7)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>14/126 (11.1)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>Halofantrine</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<LINK REF="STD-Van-Agtmael-1999a" TYPE="STUDY">Van Agtmael 1999a</LINK>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Vomiting</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1/51 (2.0)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>7/52 (14.0)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Headache</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>7/51 (14.0)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>4/52 (8.0)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Sleep disorders</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>4/51 (8.0)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>6/52 (12.0)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Diarrhoea</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>3/51 (6.0)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>6/52 (12.0)</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>
<SUP>a</SUP>Number of participants with event calculated from percentage using the total number of participants originally randomized to each group.</P>
</FOOTNOTES>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-09" MODIFIED="2008-07-17 14:30:35 +0100" MODIFIED_BY="[Empty name]" NO="9">
<TITLE>Severe adverse events</TITLE>
<TABLE COLS="4" ROWS="7">
<TR>
<TH ALIGN="LEFT" ROWSPAN="2" VALIGN="BOTTOM">
<P>Comparator</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="2" VALIGN="BOTTOM">
<P>Trial</P>
</TH>
<TH ALIGN="CENTER" COLSPAN="2" VALIGN="BOTTOM">
<P>Number with event</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>Artemether-lumefantrine</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>Comparator</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Sulfadoxine-pyrimethamine</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="STD-Von-Seidlein-1998" TYPE="STUDY">Von Seidlein 1998</LINK>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Anaemia (4), vomiting (1), splenomegaly (1), conjunctivitis (1)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Anaemia (1), fever (1), glomerulonephritis (1), proteinuria (1), haematuria (1)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Mefloquine</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="STD-Looareesuwan-1999" TYPE="STUDY">Looareesuwan 1999</LINK>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Severe fatigue (1)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Pneumonia (1), AIDS-related (1)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Halofantrine</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="STD-Van-Agtmael-1999a" TYPE="STUDY">Van Agtmael 1999a</LINK>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Haemolytic anaemia (1), hepatitis A (1)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Prolonged QTc interval (treatment stopped) (1), pneumonia (1)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>Chloroquine</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="STD-Hatz-1998" TYPE="STUDY">Hatz 1998</LINK>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Treatment stopped (reason not stated) (8), treated for adverse events (7)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Treated for adverse events (7)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="STD-Kshirsagar-2000" TYPE="STUDY">Kshirsagar 2000</LINK>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>None</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Died from cerebral malaria (1)</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
</ADDITIONAL_TABLES>
<ANALYSES_AND_DATA CALCULATED_DATA="YES">
<COMPARISON ID="CMP-001" NO="1">
<NAME>Artemether-lumefantrine (4 doses) versus sulfadoxine-pyrimethamine</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="8" EVENTS_2="3" I2="0.0" I2_Q="0.0" ID="CMP-001.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="119" TOTAL_2="128" WEIGHT="0.0" Z="0.0">
<NAME>Total failure by day 14</NAME>
<GROUP_LABEL_1>AL</GROUP_LABEL_1>
<GROUP_LABEL_2>SP</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours AL</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours SP</GRAPH_LABEL_2>
<DICH_DATA CI_END="10.558736320358957" CI_START="0.7792046516887627" EFFECT_SIZE="2.8683473389355743" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="3" LOG_CI_END="1.023611944529736" LOG_CI_START="-0.10834846347449853" LOG_EFFECT_SIZE="0.4576317405276188" ORDER="19" O_E="0.0" SE="0.6649191469560758" STUDY_ID="STD-Von-Seidlein-1998" TOTAL_1="119" TOTAL_2="128" VAR="0.4421174719887955" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="2" EVENTS_2="3" I2="0.0" I2_Q="0.0" ID="CMP-001.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="119" TOTAL_2="128" WEIGHT="0.0" Z="0.0">
<NAME>Total failure by day 14 (excluding new infections)</NAME>
<GROUP_LABEL_1>AL</GROUP_LABEL_1>
<GROUP_LABEL_2>SP</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours AL</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours SP</GRAPH_LABEL_2>
<DICH_DATA CI_END="4.217077245028239" CI_START="0.12193599943062723" EFFECT_SIZE="0.7170868347338936" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" LOG_CI_END="0.6250115561446412" LOG_CI_START="-0.9138680577453284" LOG_EFFECT_SIZE="-0.14442825080034363" ORDER="20" O_E="0.0" SE="0.9039455027759116" STUDY_ID="STD-Von-Seidlein-1998" TOTAL_1="119" TOTAL_2="128" VAR="0.8171174719887955" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="1" EVENTS_2="10" I2="0.0" I2_Q="0.0" ID="CMP-001.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" NO="3" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="41" TOTAL_2="74" WEIGHT="0.0" Z="0.0">
<NAME>Gametocyte carriage by day 4</NAME>
<GROUP_LABEL_1>AL</GROUP_LABEL_1>
<GROUP_LABEL_2>SP</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours AL</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours SP</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.3604406689714978" CI_START="0.023945070485377487" EFFECT_SIZE="0.18048780487804877" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="10" LOG_CI_END="0.13367960624062078" LOG_CI_START="-1.6207838802181394" LOG_EFFECT_SIZE="-0.7435521369887593" ORDER="21" O_E="0.0" SE="1.0305805366801992" STUDY_ID="STD-Von-Seidlein-1998" TOTAL_1="41" TOTAL_2="74" VAR="1.0620962425840474" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="37" I2="0.0" I2_Q="0.0" ID="CMP-001.04" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" NO="4" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="125" TOTAL_2="128" WEIGHT="0.0" Z="0.0">
<NAME>Gametocyte carriage by day 15</NAME>
<GROUP_LABEL_1>AL</GROUP_LABEL_1>
<GROUP_LABEL_2>SP</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours AL</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours SP</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.21990646123421734" CI_START="8.473792277439156E-4" EFFECT_SIZE="0.013650793650793651" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="37" LOG_CI_END="-0.6577620101246906" LOG_CI_START="-3.071922186295337" LOG_EFFECT_SIZE="-1.864842098210014" ORDER="22" O_E="0.0" SE="1.4180896377682417" STUDY_ID="STD-Von-Seidlein-1998" TOTAL_1="125" TOTAL_2="128" VAR="2.010978220745663" WEIGHT="0.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-002" NO="2">
<NAME>Artemether-lumefantrine (4 doses) versus mefloquine</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="35" EVENTS_2="21" I2="0.0" I2_Q="0.0" ID="CMP-002.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="5.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="114" TOTAL_2="119" WEIGHT="0.0" Z="0.0">
<NAME>Total failure by day 28</NAME>
<GROUP_LABEL_1>AL</GROUP_LABEL_1>
<GROUP_LABEL_2>Mefloquine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours AL</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours mefloquine</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.800745205348502" CI_START="1.080707382395873" EFFECT_SIZE="1.739766081871345" ESTIMABLE="YES" EVENTS_1="35" EVENTS_2="21" LOG_CI_END="0.4472736011675846" LOG_CI_START="0.03370811817724445" LOG_EFFECT_SIZE="0.24049085967241451" ORDER="23" O_E="0.0" SE="0.24293041189068315" STUDY_ID="STD-Looareesuwan-1999" TOTAL_1="114" TOTAL_2="119" VAR="0.05901518502137697" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="62" EVENTS_2="74" I2="0.0" I2_Q="0.0" ID="CMP-002.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="2.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="126" TOTAL_2="126" WEIGHT="0.0" Z="0.0">
<NAME>Gametocyte carriage within the first 72 h</NAME>
<GROUP_LABEL_1>AL</GROUP_LABEL_1>
<GROUP_LABEL_2>Mefloquine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours AL</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours mefloquine</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.054491437007138" CI_START="0.6656974327881918" EFFECT_SIZE="0.8378378378378378" ESTIMABLE="YES" EVENTS_1="62" EVENTS_2="74" LOG_CI_END="0.023043057403482482" LOG_CI_START="-0.17672311786892705" LOG_EFFECT_SIZE="-0.07684003023272232" ORDER="24" O_E="0.0" SE="0.11734364021352907" STUDY_ID="STD-Looareesuwan-1999" TOTAL_1="126" TOTAL_2="126" VAR="0.013769529898562158" WEIGHT="0.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-003" NO="3">
<NAME>Artemether-lumefantrine (4 doses) versus halofantrine</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="8" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-003.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="45" TOTAL_2="41" WEIGHT="0.0" Z="0.0">
<NAME>Total failure by day 28</NAME>
<GROUP_LABEL_1>AL</GROUP_LABEL_1>
<GROUP_LABEL_2>Mefloquine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours AL</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours mefloquine</GRAPH_LABEL_2>
<DICH_DATA CI_END="260.7514404679249" CI_START="0.9239618588527281" EFFECT_SIZE="15.521739130434783" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="0" LOG_CI_END="2.416226716276107" LOG_CI_START="-0.034345956086906326" LOG_EFFECT_SIZE="1.1909403800946003" ORDER="25" O_E="0.0" SE="1.439478518276401" STUDY_ID="STD-Van-Agtmael-1999a" TOTAL_1="45" TOTAL_2="41" VAR="2.072098404579223" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="1" EVENTS_2="8" I2="0.0" I2_Q="0.0" ID="CMP-003.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="5" TOTAL_2="9" WEIGHT="0.0" Z="0.0">
<NAME>Gametocyte carriage within the first 72 h</NAME>
<GROUP_LABEL_1>AL</GROUP_LABEL_1>
<GROUP_LABEL_2>Mefloquine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours AL</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours mefloquine</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.3185625012843705" CI_START="0.038394084429587354" EFFECT_SIZE="0.225" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="8" LOG_CI_END="0.12010072064411163" LOG_CI_START="-1.4157356844213866" LOG_EFFECT_SIZE="-0.6478174818886375" ORDER="26" O_E="0.0" SE="0.9021579068482906" STUDY_ID="STD-Van-Agtmael-1999a" TOTAL_1="5" TOTAL_2="9" VAR="0.8138888888888889" WEIGHT="0.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-004" NO="4">
<NAME>Artemether-lumefantrine (4 doses) versus chloroquine</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="46" EVENTS_2="174" I2="0.0" I2_Q="0.0" ID="CMP-004.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="183" TOTAL_2="195" WEIGHT="0.0" Z="0.0">
<NAME>Total failure by day 28</NAME>
<GROUP_LABEL_1>AL</GROUP_LABEL_1>
<GROUP_LABEL_2>Chloroquine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours AL</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours chloroquine</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.48875678744408824" CI_START="0.30131248749427375" EFFECT_SIZE="0.38375581220938954" ESTIMABLE="YES" EVENTS_1="43" EVENTS_2="113" LOG_CI_END="-0.31090719843690395" LOG_CI_START="-0.5209828691979517" LOG_EFFECT_SIZE="-0.4159450338174278" ORDER="27" O_E="0.0" SE="0.12339948889638082" STUDY_ID="STD-Hatz-1998" TOTAL_1="118" TOTAL_2="119" VAR="0.015227433859888012" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.17462006155382126" CI_START="0.01893604049731943" EFFECT_SIZE="0.0575031525851198" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="61" LOG_CI_END="-0.7579058630266643" LOG_CI_START="-1.7227108262796733" LOG_EFFECT_SIZE="-1.2403083446531689" ORDER="28" O_E="0.0" SE="0.5667312112764098" STUDY_ID="STD-Kshirsagar-2000" TOTAL_1="65" TOTAL_2="76" VAR="0.3211842658348267" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.003123581504427159" CI_END="0.9907291326198288" CI_START="0.625624909021355" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.7872895423286698" ESTIMABLE="YES" EVENTS_1="63" EVENTS_2="72" I2="0.0" I2_Q="0.0" ID="CMP-004.02" LOG_CI_END="-0.004045066289761177" LOG_CI_START="-0.203685968331893" LOG_EFFECT_SIZE="-0.10386551731082712" METHOD="MH" NO="2" P_CHI2="0.9554302544012443" P_Q="0.0" P_Z="0.04141127594732391" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="219" TOTAL_2="208" WEIGHT="100.0" Z="2.03938843275594">
<NAME>Gametocyte carriage within the first 72 h</NAME>
<GROUP_LABEL_1>AL</GROUP_LABEL_1>
<GROUP_LABEL_2>Chloroquine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours AL</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours chloroquine</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.64208476483138" CI_START="0.3897484549561115" EFFECT_SIZE="0.8" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="15" LOG_CI_END="0.21539557175319413" LOG_CI_START="-0.40921559776930694" LOG_EFFECT_SIZE="-0.09691001300805639" ORDER="29" O_E="0.0" SE="0.3668996928526714" STUDY_ID="STD-Hatz-1998" TOTAL_1="130" TOTAL_2="130" VAR="0.1346153846153846" WEIGHT="19.800806260374674"/>
<DICH_DATA CI_END="0.9813109964648964" CI_START="0.626604006476638" EFFECT_SIZE="0.7841513897102307" ESTIMABLE="YES" EVENTS_1="51" EVENTS_2="57" LOG_CI_END="-0.00819333447109339" LOG_CI_START="-0.2030068325868814" LOG_EFFECT_SIZE="-0.10560008352898738" ORDER="30" O_E="0.0" SE="0.11443441313558222" STUDY_ID="STD-Kshirsagar-2000" TOTAL_1="89" TOTAL_2="78" VAR="0.013095234909685113" WEIGHT="80.19919373962533"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-005" NO="5">
<NAME>Artemether-lumefantrine versus mefloquine plus artesunate</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="49" EVENTS_2="7" I2="0.0" I2_Q="0.0" ID="CMP-005.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="273" TOTAL_2="264" WEIGHT="0.0" Z="0.0">
<NAME>Total failure by day 28</NAME>
<GROUP_LABEL_1>AL</GROUP_LABEL_1>
<GROUP_LABEL_2>Mef plus art</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours AL</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours mef plus art</GRAPH_LABEL_2>
<DICH_DATA CI_END="14.673609695716248" CI_START="3.1227820663975963" EFFECT_SIZE="6.769230769230769" ESTIMABLE="YES" EVENTS_1="49" EVENTS_2="7" LOG_CI_END="1.1665369630656572" LOG_CI_START="0.4945416766210065" LOG_EFFECT_SIZE="0.8305393198433318" ORDER="31" O_E="0.0" SE="0.3947333576879037" STUDY_ID="STD-Van-Vugt-1998a" TOTAL_1="273" TOTAL_2="264" VAR="0.15581442367156653" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="40" EVENTS_2="6" I2="0.0" I2_Q="0.0" ID="CMP-005.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="273" TOTAL_2="264" WEIGHT="0.0" Z="0.0">
<NAME>Total failure by day 28 (excluding new infections)</NAME>
<GROUP_LABEL_1>AL</GROUP_LABEL_1>
<GROUP_LABEL_2>Mef plus art</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours AL</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours mef plus art</GRAPH_LABEL_2>
<DICH_DATA CI_END="14.9516403181154" CI_START="2.7797849583561236" EFFECT_SIZE="6.446886446886447" ESTIMABLE="YES" EVENTS_1="40" EVENTS_2="6" LOG_CI_END="1.17468884095661" LOG_CI_START="0.4440112005901774" LOG_EFFECT_SIZE="0.8093500207733938" ORDER="32" O_E="0.0" SE="0.4292036628638952" STUDY_ID="STD-Van-Vugt-1998a" TOTAL_1="273" TOTAL_2="264" VAR="0.18421578421578422" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="46" EVENTS_2="16" I2="0.0" I2_Q="0.0" ID="CMP-005.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" NO="3" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="248" TOTAL_2="230" WEIGHT="0.0" Z="0.0">
<NAME>Total failure by day 63</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Mef plus art</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours mef plus art</GRAPH_LABEL_2>
<DICH_DATA CI_END="4.574634152987657" CI_START="1.5540738060295345" EFFECT_SIZE="2.6663306451612905" ESTIMABLE="YES" EVENTS_1="46" EVENTS_2="16" LOG_CI_END="0.6603563679780349" LOG_CI_START="0.19147164045601694" LOG_EFFECT_SIZE="0.4259140042170259" ORDER="33" O_E="0.0" SE="0.27542520996326747" STUDY_ID="STD-Van-Vugt-1998a" TOTAL_1="248" TOTAL_2="230" VAR="0.07585904628330996" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="34" EVENTS_2="24" I2="0.0" I2_Q="0.0" ID="CMP-005.04" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" NO="4" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="309" TOTAL_2="307" WEIGHT="0.0" Z="0.0">
<NAME>Gametocyte carriage within the first 72 h</NAME>
<GROUP_LABEL_1>AL</GROUP_LABEL_1>
<GROUP_LABEL_2>Mef plus art</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours AL</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours mef plus art</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.3161576048183523" CI_START="0.855316863667835" EFFECT_SIZE="1.407497303128371" ESTIMABLE="YES" EVENTS_1="34" EVENTS_2="24" LOG_CI_END="0.36476810798031933" LOG_CI_START="-0.06787296521431743" LOG_EFFECT_SIZE="0.14844757138300094" ORDER="34" O_E="0.0" SE="0.2541355080023814" STUDY_ID="STD-Van-Vugt-1998a" TOTAL_1="309" TOTAL_2="307" VAR="0.06458485642762844" WEIGHT="0.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-006" NO="6">
<NAME>Artemether-lumefantrine (4 doses) versus artemether-lumefantrine (6 doses)</NAME>
<DICH_OUTCOME CHI2="0.26218905074319876" CI_END="19.881370985727493" CI_START="2.9870657677629424" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="RR" EFFECT_SIZE="7.706293706293706" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="5" I2="0.0" I2_Q="0.0" ID="CMP-006.01" LOG_CI_END="1.2984463293070923" LOG_CI_START="0.47524478479431653" LOG_EFFECT_SIZE="0.8868455570507043" METHOD="MH" NO="1" P_CHI2="0.6086202642213533" P_Q="0.0" P_Z="2.410840635439801E-5" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="104" TOTAL_2="202" WEIGHT="100.0" Z="4.222988557917525">
<NAME>Total failure by day 28</NAME>
<GROUP_LABEL_1>AL (4 doses)</GROUP_LABEL_1>
<GROUP_LABEL_2>AL (6 doses)</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours AL (4 doses)</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours AL (6 doses)</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="21.378067161469925" CI_START="1.771433413468761" DF="0.0" EFFECT_SIZE="6.153846153846154" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="3" I2="0.0" ID="CMP-006.01.01" LOG_CI_END="1.3299684371190716" LOG_CI_START="0.24832483225114196" LOG_EFFECT_SIZE="0.7891466346851068" NO="1" P_CHI2="1.0" P_Z="0.00423767918594209" STUDIES="1" TAU2="0.0" TOTAL_1="52" TOTAL_2="96" WEIGHT="61.55844155844156" Z="2.859905010380292">
<NAME>6-dose regimen taken over 60 h</NAME>
<DICH_DATA CI_END="21.378067161469925" CI_START="1.771433413468761" EFFECT_SIZE="6.153846153846154" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="3" LOG_CI_END="1.3299684371190716" LOG_CI_START="0.24832483225114196" LOG_EFFECT_SIZE="0.7891466346851068" ORDER="35" O_E="0.0" SE="0.6353628077216178" STUDY_ID="STD-Van-Vugt-1998a" TOTAL_1="52" TOTAL_2="96" VAR="0.40368589743589745" WEIGHT="61.55844155844156"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="44.840234805736344" CI_START="2.316739342350299" DF="0.0" EFFECT_SIZE="10.192307692307692" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="2" I2="0.0" ID="CMP-006.01.02" LOG_CI_END="1.6516678781104606" LOG_CI_START="0.3648771738215195" LOG_EFFECT_SIZE="1.00827252596599" NO="2" P_CHI2="1.0" P_Z="0.0021299834690449906" STUDIES="1" TAU2="0.0" TOTAL_1="52" TOTAL_2="106" WEIGHT="38.44155844155844" Z="3.07148292400289">
<NAME>6-dose regimen taken over 96 h</NAME>
<DICH_DATA CI_END="44.840234805736344" CI_START="2.316739342350299" EFFECT_SIZE="10.192307692307692" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="2" LOG_CI_END="1.6516678781104606" LOG_CI_START="0.3648771738215195" LOG_EFFECT_SIZE="1.00827252596599" ORDER="36" O_E="0.0" SE="0.7558672294160396" STUDY_ID="STD-Van-Vugt-1998a" TOTAL_1="52" TOTAL_2="106" VAR="0.5713352685050798" WEIGHT="38.44155844155844"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES/>
<FEEDBACK/>
<APPENDICES/>
<EXTENSIONS/>
</COCHRANE_REVIEW>